

## Diet-induced alteration of intestinal stem cell function underlies obesity and prediabetes in mice

Alexandra Aliluev, Sophie Tritschler, Michael Sterr, Lena Oppenländer, Julia Hinterdobler, Tobias Greisle, Martin Irmeler, Johannes Beckers, Na Sun, Axel Walch, Kerstin Stemmer, Alida Kindt, Jan Krumsiek, Matthias H. Tschöp, Malte D. Luecken, Fabian J. Theis, Heiko Lickert, Anika Böttcher

### Angaben zur Veröffentlichung / Publication details:

Aliluev, Alexandra, Sophie Tritschler, Michael Sterr, Lena Oppenländer, Julia Hinterdobler, Tobias Greisle, Martin Irmeler, et al. 2021. "Diet-induced alteration of intestinal stem cell function underlies obesity and prediabetes in mice." *Nature Metabolism* 3 (9): 1202–16.  
<https://doi.org/10.1038/s42255-021-00458-9>.



OPEN

# Diet-induced alteration of intestinal stem cell function underlies obesity and prediabetes in mice

Alexandra Aliluev<sup>1,2,12</sup>, Sophie Tritschler<sup>1,2,3,4,12</sup>, Michael Sterr<sup>1,2</sup>, Lena Oppenländer<sup>1,2</sup>, Julia Hinterdobler<sup>1</sup>, Tobias Greisle<sup>1,2</sup>, Martin Irmeler<sup>5</sup>, Johannes Beckers<sup>2,5,6</sup>, Na Sun<sup>7</sup>, Axel Walch<sup>7</sup>, Kerstin Stemmer<sup>8,9</sup>, Alida Kindt<sup>10</sup>, Jan Krumsiek<sup>3</sup>, Matthias H. Tschöp<sup>2,8,10</sup>, Malte D. Luecken<sup>10</sup>, Fabian J. Theis<sup>3,11,13</sup>✉, Heiko Lickert<sup>1,2,11,13</sup>✉ and Anika Böttcher<sup>1,2,13</sup>✉

**Excess nutrient uptake and altered hormone secretion in the gut contribute to a systemic energy imbalance, which causes obesity and an increased risk of type 2 diabetes and colorectal cancer. This functional maladaptation is thought to emerge at the level of the intestinal stem cells (ISCs). However, it is not clear how an obesogenic diet affects ISC identity and fate. Here we show that an obesogenic diet induces ISC and progenitor hyperproliferation, enhances ISC differentiation and cell turnover and changes the regional identities of ISCs and enterocytes in mice. Single-cell resolution of the enteroendocrine lineage reveals an increase in progenitors and peptidergic enteroendocrine cell types and a decrease in serotonergic enteroendocrine cell types. Mechanistically, we link increased fatty acid synthesis, Ppar signaling and the *Insr-Igf1r-Akt* pathway to mucosal changes. This study describes molecular mechanisms of diet-induced intestinal maladaptation that promote obesity and therefore underlie the pathogenesis of the metabolic syndrome and associated complications.**

Diet-induced obesity is a serious public health and economic problem. Obese people are at higher risk of developing type 2 diabetes (T2D), cardiovascular diseases and cancer, all leading causes of death worldwide (<https://www.who.int>). Today, bariatric surgery is the most effective treatment to achieve long-term weight loss and notably leads to diabetes remission<sup>1</sup>. Surgical procedures cause profound changes in secretion of gut hormones with beneficial effects on whole body metabolism, appetite and food intake<sup>2</sup>. These findings suggest gut hormones as candidates for new therapies against obesity and diabetes<sup>3</sup>.

The gut, as the body's digestive and largest endocrine system, serves as a central regulator of energy and glucose homeostasis and quickly responds to dietary and nutritional changes<sup>4–8</sup>. Constant overnutrition is thought to lead to intestinal maladaptation and dysfunction and to contribute to the development of obesity and prediabetes<sup>8</sup>. This is evident as two hallmarks of obesity, excessive food intake and a reduced stimulation of postprandial insulin secretion by gut hormones, are linked to impaired gut function<sup>9</sup>. Moreover, differences in gut morphology and physiology have been observed between lean and obese individuals<sup>8,10,11</sup>. Tackling gut dysfunction at an early stage of disease might therefore be a promising treatment option to fight obesity and the resulting risks and complications.

Intestinal functions are carried out by specialized epithelial cells lining the gut: absorptive enterocytes, antimicrobial-peptide-secreting Paneth cells, hormone-secreting enteroendocrine cells (EECs), mucus-secreting goblet and chemosensory tuft cells. The cells of the intestinal epithelium are constantly generated from ISCs<sup>12</sup>.

ISC identity is defined by multi-lineage potential and self-renewal capacity, but also by properties that are not hard-wired, such as the proliferative, epigenetic and metabolic state<sup>12,13</sup>. High cell turnover and cellular plasticity contribute to the natural adaptive capacity of the gut, but the mechanisms underlying maladaptation in response to an obesogenic diet are still unclear. Specifically, we do not know whether the hormonal imbalance and increased absorptive capacity emerge at the level of early lineage commitment from ISCs<sup>9,14</sup>. Moreover, the functions of enterocytes and EECs differ between gut regions<sup>15–17</sup>. Proximal enterocytes, for instance, are specialized to absorb iron and nutrients (carbohydrates, fat and protein), whereas distal enterocytes absorb bile acids and vitamin B12. Proximal EEC types secrete serotonin and ghrelin, whereas distally located EECs preferentially secrete Glp-1 (ref. 17). Gut functions are also spatially compartmentalized along the crypt–villus axis. Enterocytes shift their expression profile from an antimicrobial to a nutrient absorption to an immunomodulatory program while migrating from the bottom of the villus to its tip. The spatial–functional compartmentalization of nutrient absorption is achieved through zoned expression of nutrient transporters, with the highest expression of carbohydrate and amino acid transporters in the mid-villus region and of apolipoproteins and fatty acid transporters, such as *Apoa4* and *Fabp1*, at the villus tip<sup>18</sup>. Similarly, enteroendocrine cell types switch their hormone expression pattern along the crypt–villus axis<sup>19</sup>. Regional identities are thought to be determined at the level of the ISCs by epigenetic mechanisms, and the crypt–villus compartmentalization is at least partly established by growth-factor

<sup>1</sup>Institute of Diabetes and Regeneration Research, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany. <sup>2</sup>German Center for Diabetes Research (DZD), Neuherberg, Germany. <sup>3</sup>Institute of Computational Biology, Helmholtz Center Munich, Neuherberg, Germany. <sup>4</sup>School of Life Sciences Weihenstephan, Technical University of Munich, Freising, Germany. <sup>5</sup>Institute of Experimental Genetics, Helmholtz Center Munich, Neuherberg, Germany. <sup>6</sup>Technical University of Munich, Freising, Germany. <sup>7</sup>Research Unit of Analytical Pathology, Helmholtz Center Munich, Neuherberg, Germany. <sup>8</sup>Institute of Diabetes and Obesity, Helmholtz Diabetes Center, Helmholtz Center Munich, Neuherberg, Germany. <sup>9</sup>Rudolf-Buchheim-Institute of Pharmacology, Justus Liebig University, Giessen, Germany. <sup>10</sup>Division of Metabolic Diseases, Department of Medicine, Technical University of Munich, Munich, Germany. <sup>11</sup>Technical University of Munich, Munich, Germany. <sup>12</sup>These authors contributed equally: Alexandra Aliluev, Sophie Tritschler. <sup>13</sup>These authors jointly supervised this work: Fabian J. Theis, Heiko Lickert, Anika Böttcher. ✉e-mail: [fabian.theis@helmholtz-muenchen.de](mailto:fabian.theis@helmholtz-muenchen.de); [heiko.lickert@helmholtz-muenchen.de](mailto:heiko.lickert@helmholtz-muenchen.de); [anika.boettcher@helmholtz-muenchen.de](mailto:anika.boettcher@helmholtz-muenchen.de)

gradients, but it is unknown whether and how the compartmentalization of gut functions is affected by an obesogenic diet<sup>20,21</sup>.

Developing pharmacological approaches to counteract obesity and diabetes require in-depth understanding of the mechanisms that underlie maladaptation and endocrine dysfunction in the gut, specifically during the transition from a healthy to an obese and to a prediabetic state. In this study we combined single-cell profiling with genetic lineage labelling and tracing of ISC fate decisions and in situ metabolomics to elucidate the cellular and molecular mechanisms that underlie intestinal maladaptation to an obesogenic western-style high-fat/high-sugar diet (HFHSD) in mice.

## Results

### HFHSD remodels the intestinal mucosa and leads to obesity.

To study mechanisms of intestinal maladaptation to an HFHSD, we maintained male *Foxa2*-Venus fusion (FVF) reporter mice on a diet regimen for 12 weeks<sup>22</sup>. Over this time, mice on an HFHSD gained significantly more body weight (fat and lean mass) than did control diet (CD)-fed mice, and this was accompanied by an increase in length and weight of the small intestine (SI), increased villus length and decreased crypt density (Extended Data Fig. 1a–l). Crypt depth, number of cells per crypt and cell sizes in crypts and villi were not changed (Extended Data Fig. 1k,m–p). Histological assessment of the SI mucosa showed cellular fat inclusions in the villi of HFHSD-fed mice, suggesting disturbances in fatty acid metabolism in the gut epithelium (Extended Data Fig. 1q). Metabolic assessment showed that our diet-induced obese mice developed prediabetes, which was characterized by fasting hyperglycaemia, impaired glucose tolerance and pronounced hyperinsulinaemia as well as insulin resistance (Extended Data Fig. 1r–u). Thus, an HFHSD changes mucosal morphology, which is indicative of altered ISC homeostasis and lineage recruitment.

**HFHSD alters ISC lineage allocation and regional identity.** To dissect the metabolic impact of an HFHSD on ISC lineage recruitment, we employed single-cell RNA-sequencing (scRNA-seq) of crypt cells from the SI of CD- and HFHSD-fed FVF reporter mice (Fig. 1a). FVF-lineage labelling enabled us to flow sort and enrich for ISCs and EECs, cell types that together usually make up less than 6% of the intestinal epithelial cells (Fig. 1a and Extended Data Fig. 2a)<sup>17</sup>. This enrichment strategy not only allowed us to assess compositional changes on an HFHSD, but also to molecularly and functionally characterize rare crypt-cell types. We profiled 27,687 cells obtained from three biological replicates of CD- and HFHSD-fed mice and detected on average 3,500 genes per cell (Extended Data Fig. 2b). Unsupervised graph-based clustering and annotation based on known marker genes revealed all mature intestinal cell lineages as well as ISCs and distinct progenitor states for each intestinal lineage (Fig. 1b,c and Extended Data Fig. 2c,d). Lineage marker gene expression as well as the expression of known


regulators that drive intestinal lineage decisions toward the absorptive (for example *Notch1*) and secretory lineages (*Dll1*, *Dll4* and *Atoh1*) and PAGA topology<sup>23</sup> were unchanged between diet conditions (Fig. 1c, Extended Data Fig. 2c–f and Supplementary Table 1). Corresponding subtypes showed high correlation in their transcriptomes, indicating that an HFHSD did not alter lineage identities (Extended Data Fig. 2g). Instead, we observed a shift of cell densities indicating that an HFHSD impacts the composition of the mucosal epithelium (Fig. 1d,e and Extended Data Fig. 2d,h). Note that we excluded the Paneth cell lineage from the scRNA-seq analysis because of reported sampling issues, which might impact cell-type ratios<sup>17</sup>. To assess whether the HFHSD affects regional subtypes, we separated cell types into proximal and distal cells using recently described regional signature genes (Extended Data Fig. 3a)<sup>17</sup>. We found that the fractions of ISCs, enterocytes and goblet cells with proximal identity increased in mice fed an HFHSD (Fig. 1f,g and Extended Data Fig. 3b). Together, these data suggest that an HFHSD boosts formation of the absorptive and goblet cell lineage and promotes proximal cell identities, indicating that the intestine adapts cell-type composition and specific cellular functions to nutrient availability.

**Altered lineage relations in the crypt translate into the villus.** As our scRNA-seq experiment indicated alterations of lineage abundances in the crypt on HFHSD, we next performed short-term genetic lineage tracing of ISC fate decisions using a dual-fluorescent inducible Cre-reporter *Foxa2*<sup>2nEGFP-CreERT2/+;Gt(Rosa)26<sup>mTmG</sup>/+</sup> mouse (Fig. 2a)<sup>24,25</sup> to determine how these changes impact the composition of the mature villus compartment. *Foxa2* is expressed in quiescent and rapidly dividing ISCs (Supplementary Fig. 1). In this mouse model, *Foxa2* expression-driven CreERT2 induces a switch from membrane-Tomato (mT) to membrane-GFP (mG) in ISCs after tamoxifen administration. At 48 h after Cre-ERT2 activation by tamoxifen, we observed labelled mG-positive ISCs next to Paneth cells at the crypt bottom and labelled single cells and small cell clusters in duodenal crypts at similar frequencies in CD- and HFHSD-fed mice (Extended Data Fig. 4a). To determine the effect of an obesogenic diet on ISC lineage recruitment, we analysed the abundance of mature enterocytes, goblet cells and EECs in Cre-reporter labelled mG-positive lineage ribbons in the villi of CD- and HFHSD-fed mice 70 h after tamoxifen induction (Fig. 2b). In mice fed an HFHSD, longer ribbons (>6 cells) appeared more frequently, suggesting higher ISC or progenitor proliferation or increased cell turnover (Fig. 2c,d and Extended Data Fig. 4b). Within the lineage ribbons, total numbers of villin<sup>+</sup> enterocytes and Muc2<sup>+</sup> goblet cells were increased, whereas the number of ChgA<sup>+</sup> EECs was reduced (Fig. 2c,d). The relative abundances of enterocytes and ChgA<sup>+</sup> EECs within lineage ribbons were diminished owing to the large increase in goblet cell numbers in mice fed an HFHSD (Fig. 2c and Extended Data Fig. 4c). In accordance,


**Fig. 1 | HFHSD alters lineage allocation from ISCs and shifts the regional identity of cells.** **a**, Experimental design for FVF-based SI crypt-cell enrichment by flow cytometry and scRNA-seq. Single FVF<sup>+</sup> and whole crypt cells from SI crypts of CD- and HFHSD-fed FVF mice were isolated in equal numbers by flow cytometry and combined for each sample. FVF-enriched single-cell samples were then transcriptionally profiled by scRNA-seq. **b**, Uniform manifold approximation and projection (UMAP) plot of 27,687 profiled single SI crypt cells. Colours highlight clustering into major intestinal cell types based on the expression of previously published marker genes. One cluster of cells could not be assigned owing to a missing marker gene signature (NA). **c**, Heatmap depicting scaled expression of cell-type-specific gene signatures in CD- and HFHSD-derived cells. Cells are represented in columns and genes are represented in rows. Colour bars indicate cell types assigned to both cells and genes. Selected known marker genes for every lineage are indicated. **d,e**, Cell-type composition differences in CD- and HFHSD-derived single-cell samples visualized by cell density projected onto the two-dimensional UMAP embedding (**d**) and quantified as proportions over cell types (mean ± s.e.m. of biologically independent samples, *n* = 3 mice per group, Dirichlet multinomial model) (**e**). Densities were estimated using Gaussian kernels. \* Indicates a credible shift (95% highest posterior density interval of the frequency shift modelled by a Dirichlet multinomial model does not overlap 0). *n* = 3 CD mice, *n* = 3 HFHSD mice. **f**, UMAP coloured by the regional identities of cells in ISCs and goblet cell and enterocyte cell lineage. Subclusters were classified on the basis of expression of regional marker genes. **g**, Proportions of cells with proximal or distal identity in ISCs and enterocyte and goblet cell lineage (mean ± s.e.m. of biologically independent samples). *n* = 3 CD mice, *n* = 3 HFHSD mice.

goblet cell numbers in the duodenal villi were increased and numbers of ChgA<sup>+</sup> EECs were reduced in the duodenum and ileum of HFHSD-fed FVF mice (Fig. 2e–j and Extended Data Fig. 4d). Note that the number of ileal goblet cells was not altered, suggesting that gut regions are differently affected by an HFHSD (Extended Data

Fig. 4e). As we excluded Paneth cells from our scRNA-seq analysis, we determined the Paneth cell numbers in situ and found no difference between CD- and HFHSD-fed mice (Extended Data Fig. 4f,g). To understand whether the shift in regional identity in crypt cells translates to the villi and results in altered function, we performed







**Fig. 2 | Altered lineage relations in the crypt translate into the mature villus compartment.** **a**, *Foxa2*<sup>nEGFP-CreERT2/+</sup>; *Gt(Rosa26)*<sup>mTmG/+</sup> lineage-tracing model. mTmG<sup>+</sup> Foxa2-negative cells (red) convert into mG Foxa2-lineage-positive cells (green) upon Foxa2-promoter-driven Cre expression via an intermediate (mTmG<sup>+</sup>, yellow) state. pCA, chicken β-actin core promoter with a CMV enhancer. **b**, Experimental scheme of short-term lineage tracing of Foxa2-positive cells using the *Foxa2*<sup>nEGFP-CreERT2/+</sup>; *Gt(Rosa26)*<sup>mTmG/+</sup> mouse model. **c,d**, Representative laser scanning microscopy (LSM) images of Cre-driven recombination in the duodenum of CD- and HFHSD-fed *Foxa2*<sup>nEGFP-CreERT2/+</sup>; *Gt(Rosa26)*<sup>mTmG/+</sup> (**c**) and analysis of lineage-positive cells (**d**) 70h after tamoxifen induction. Single converted mG<sup>+</sup> cells and lineage ribbons (green) containing Muc2<sup>+</sup> goblet cells (red), ChgA<sup>+</sup> EECs (white) and villin<sup>+</sup> enterocytes (white) are observed in crypts and villi. Scale bar, 100 μm. For Foxa2-lineage analysis, only confluent mG<sup>+</sup> cell patches located in the villi were considered (n = 3 mice per group). Data are mean ± s.e.m. Statistical significance was determined by two-tailed Student's t-test. DAPI, 4,6-diamidino-2-phenylindole. **e-j**, Abundances of mature intestinal cell types are altered in HFHSD-fed FVF mice. **e,g**, Representative LSM images (**e**) of goblet cells (Muc2<sup>+</sup>) and quantification thereof (**f,g**). Scale bar, 75 μm, n = 3 mice per group. **h-j**, Representative LSM images (**h**) of ChgA<sup>+</sup> EECs and quantification thereof (**i,j**). Scale bar, 75 μm, n = 4 mice per group. Data are mean ± s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's t-test.

scRNA-seq of villus cells from the SI (Extended Data Fig. 5a–c). We focused on enterocytes because regional and spatial compartmentalization of enterocyte function is well described and classified them into proximal and distal enterocytes using reported regional transcription factors (Extended Data Fig. 5d,e)<sup>17,18</sup>. Consistent with crypt scRNA-seq data, we also found an increased fraction of proximal-type villus enterocytes in mice fed an HFHSD (Extended Data Fig. 5f). Furthermore, proximal and distal-type enterocytes showed upregulation of functional proximal genes such as *Fabp1* and *Apoa4* (Extended Data Fig. 5g).

Next, we assessed whether enterocyte zonation is affected by an HFHSD. We inferred a pseudospacial ordering of cells using previously reported zonation markers and partitioned cells into five zones along the axis from villus bottom to tip (Extended Data Fig. 6a)<sup>18</sup>. We found that in proximal and distal enterocytes, the spatial expression pattern of several genes associated with carbohydrate and fatty acid absorption was altered in HFHSD-fed mice (Extended Data Fig. 6b)<sup>18</sup>. Analysis of *Fabp1* and *Apoa4* immunolocalization in the ileum and duodenum confirmed the proximalization of enterocytes and altered enterocyte zonation. The expression zones of *Fabp1* and *Apoa4* were enlarged on an HFHSD and reached from villus tip to villus bottom (Extended Data Fig. 6c–k).

Thus, more goblet cells and proximal-type enterocytes are generated under HFHSD conditions, which leads to morphological changes of the gut mucosa and an increase in fatty acid transport and absorption. Reduced ChgA<sup>+</sup> EEC numbers imply changes in specific EEC subsets.

### HFHSD changes the allocation of the enteroendocrine lineage.

Secreted gut hormones are critical regulators of food intake and systemic metabolism along the gut–brain–pancreas axis and hormonal imbalance is linked to the metabolic syndrome<sup>26,27</sup>. To elucidate the mechanisms underlying EEC dysfunction in response to an obesogenic diet, we first refined the clustering of our 2,865 EEC lineage cells into distinct subpopulations, which revealed five enteroendocrine progenitor (EEP) clusters characterized by expression of *Sox4*, *Ngn3*, *Arx/Isl1*, *Ghrl* and *Pax4*, respectively, and six polyhormonal EEC clusters: SILA cells (coexpress *Sct*, *Cck*, *Gcg*, *Ghrl* and *Gal*), SILP cells (coexpress *Sct*, *Cck*, *Gcg* and *Pyy*), SIK cells (coexpress *Sct*, *Cck* and *Gip*), SAKD cells (coexpress *Sct*, *Cck*, *Ghrl*, *Gip* and *Sst*), SIN cells (coexpress *Sct*, *Cck*, *Gcg* and *Nts*), enterchromaffin (EC) cells (coexpress *Sct*, *Tac1*, *Tph1* and *Reg4*<sup>+</sup> EC cells (coexpress *Sct*, *Tac1*, *Tph1*, *Ucn3* and *Reg4*) (Fig. 3a,b and Extended Data Fig. 7a,b)<sup>17,19,28</sup>. We also identified a population of heterogeneous EECs coexpressing endocrine and ISC markers that we termed *Lgr5*<sup>+</sup> EECs and which are reminiscent of *Lgr5*<sup>+</sup> label-retaining cells (Fig. 3a,b and Extended Data Fig. 7a)<sup>29</sup>. Notably, we found that *Lgr5*<sup>+</sup> EECs are characterized by active Bmp signalling, which has been shown to regulate the hormonal plasticity of EECs (Extended Data Fig. 7c)<sup>19</sup>. To determine EEC lineage hierarchy and to understand the relationship of EEP and mature clusters,

we used PAGA in combination with RNA velocity (Methods)<sup>30</sup>. The abstracted graph represents possible differentiation paths that cells follow and RNA velocity predicts the future state of a cell based on gene expression state (gene induction or repression), thus indicating the direction of differentiation. We observed two main differentiation trajectories from the *Sox4*<sup>+</sup> progenitors to mature subtypes: (1) a path via *Arx/Isl1*<sup>+</sup> and *Ghrl*<sup>+</sup> progenitors to peptidergic EECs (SILA, SILP, SIK and SAKD) and (2) a route via *Pax4*<sup>+</sup> progenitors to serotonergic EC and mature *Reg4*<sup>+</sup> EC cells (Fig. 3c). To identify transcriptional signatures and regulators of EEC lineage allocation, we extracted genes that were either only transiently expressed in a specific EEP stage or mature cell subtype (state-specific genes) or turned on with sustained expression in subsequent states (global or lineage-specific genes) (Fig. 3d, Extended Data Fig. 7a,d and Supplementary Tables 2 and 3). Transiently expressed markers in progenitor stages (for example *Sfrp5* in *Ngn3*<sup>+</sup> progenitor) are potentially important for specification. Global or lineage-specific markers (for example *Nefm* in peptidergic lineage) might regulate endocrine cell identity. Together, our data confirm EEC lineage differentiation from an early common progenitor into EC-biased (*Pax4*<sup>+</sup>) and non-EC-biased (*Arx/Isl1*<sup>+</sup>) progenitors and their respective molecular programs<sup>17,28,31</sup>. We then compared EEC lineage allocation in CD- and HFHSD-fed animals. We found that an HFHSD reduces the number of *Sox4*<sup>+</sup> early EEPs, increases the fraction of *Ngn3*<sup>+</sup> EEPs, reduces the number of *Lyz1*<sup>+</sup> BrdU<sup>+</sup> cells that correspond to label-retaining *Lgr5*<sup>+</sup> EECs and affects mature SILA and *Reg4*<sup>+</sup> EC cells, which are most abundant in the duodenum (Fig. 3e–o and Extended Data Fig. 7e–i)<sup>17</sup>. Serotonin (5-HT)<sup>+</sup> *Reg4*<sup>+</sup> EC numbers were decreased in HFHSD crypts, whereas *Ghrl*<sup>+</sup> SILA cells were more abundant in the duodenal crypts and villi (Fig. 3h–m). Numbers of ileal located SILA/SILP cells expressing *Gcg*, which encodes the incretin Glp-1, were also increased with an HFHSD (Fig. 3n,o). We next assessed whether an HFHSD induces transcriptome changes that might affect EEC lineage allocation or function. Single-cell messenger RNA expression levels of hormones did not differ between CD and HFHSD EEC subsets (Extended Data Fig. 7j). However, genes associated with metabolism (for example *Slc5a1*, *Acadl* in SIK cells), vesicular trafficking machinery and the secretome (for example *Cplx2* in EC and *Sct* in SIK cells) as well as signalling (transduction) (for example *ID1/ID3* in *Sox4*<sup>+</sup> progenitors, *Gnas* in EC cells) and transcription factors (for example *Cdx2* in *Sox4*<sup>+</sup> progenitor, *Hmgn3* in EC cells) were differentially expressed between CD and HFHSD conditions (Extended Data Fig. 7k–m and Supplementary Table 4).


Next, we examined EEC functionality by assessing hormone secretion (Extended Data Fig. 7n). Intestinal EC cells produce over 90% of the body's serotonin<sup>32</sup>. We found that basal plasma levels of serotonin were lower in mice fed an HFHSD, which correlates with reduced numbers of 5-HT<sup>+</sup> EECs (*Reg4*<sup>+</sup> EC cells) (Extended Data Fig. 7o). By contrast, despite a higher number of *Ghrl*<sup>+</sup> SILA EECs, plasma levels of ghrelin were reduced in HFHSD-fed mice

**Fig. 3 | EEC lineage formation and composition in homeostasis and upon HFHSD.** **a**, Colour-coded UMAP plot of 2,865 EEC lineage cells from CD- and HFHSD-derived samples. Cluster annotation was based on known marker genes and labelling of mature EEC subtypes as previously described<sup>17</sup>. **b**, Expression levels of selected EEC markers (hormones and transcription factors) across EEC clusters plotted in UMAP space. **c**, Streamline plot of RNA velocity projected into UMAP space showing the direction of cell differentiation along trajectories for the endocrine lineage in CD-derived samples. Arrows indicate estimated future states of cells. **d**, Heatmap showing mean expression values per cluster of genes upregulated in EEP clusters during endocrine lineage formation. Genes were selected from (pan)endocrine, lineage- and stage-specific markers (Methods). Colour bars on the side indicate expression in the progenitor populations (Fig. 3a). **e**, Cell proportions in EEC lineage subsets from CD- and HFHSD-derived samples (mean ± s.e.m. of biologically independent samples, *n* = 3 mice per group, Dirichlet multinomial model). \*Indicates a credible shift (95% highest posterior density interval of the frequency shift modeled by a Dirichlet multinomial model does not overlap 0). **f–o**, Validation of EEC frequencies in CD- and HFHSD-fed FVF mice by immunofluorescence staining. Representative LSM images (**f**) and quantification of *Ngn3*<sup>+</sup> cells in isolated small intestinal crypts (**g**). Scale bar, 10 μm, *n* = 4 mice per group. Representative LSM images (**h**) and quantification of 5-HT<sup>+</sup> cells in isolated small intestinal crypts (**i**). Scale bar, 10 μm, *n* = 4 mice per group. Representative LSM images (**j**) and quantification of *Ghrl*<sup>+</sup> cells in duodenal sections (**k–m**). Scale bar, 100 μm; crypt, *n* = 5 for CD mice and *n* = 4 HFHSD mice; villus, *n* = 4 CD and HFHSD mice. Quantification of *Gcg*<sup>+</sup> cells in ileal sections (**n,o**), *n* = 3 CD and HFHSD mice. Data are shown as mean ± s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test.

(Extended Data Fig. 7p), suggesting that *Ghrl*<sup>+</sup> EECs are functionally impaired upon HFHSD. *Glp-1* plasma levels were also increased, which corresponds with increased numbers of ileal *Gcg*<sup>+</sup> cells (Extended Data Fig. 7q). Taken together, these results show that an HFHSD impacts EEPs, alters the number of specific mature EEC subtypes and circulating gut hormone levels and affects expression

of genes that are potentially important for endocrine cell differentiation and/or function.

**HFHSD induces hyperproliferation of ISC and progenitors.** We next asked whether the increased number of *Ngn3*<sup>+</sup> EEPs, as well as the increase in villus length and higher abundance of





the enterocyte and goblet cell lineage under HFHSD conditions, resulted from enhanced proliferation. To test this, we identified proliferating cells using a cell-cycle signature score that assigns each cell to a cell-cycle state (G1, S and G2M; Methods) (Extended Data Fig. 8a). HFHSD mainly increased the proportion of cells in G2M phase, indicating that HFHSD alters cell-cycle dynamics (Fig. 4a,b). In particular, in ISCs, enterocytes, goblet cells and the early *Sox4*<sup>+</sup> and *Ngn3*<sup>+</sup> EEP clusters, the proportion of cycling cells was clearly increased (Fig. 4c and Extended Data Fig. 8b). Moreover, several genes, including the known cell-cycle regulators *Ccnb1*, *Cenpa*, *Dut*, *Pbk* and *Smc2*, which correlated with the S/G2M cell-cycle score, were differentially expressed in proliferating cells upon HFHSD, further suggesting that cell-cycle dynamics of ISCs and progenitors is accelerated (Fig. 4d and Supplementary Table 5).

To confirm the increase in proliferative activity, we first identified 5-ethynyl-2'-deoxyuridine (EdU)-positive progenitor cells 2 h after an EdU pulse. Consistent with the crypt scRNA-seq data, we found a higher number of proliferative progenitors in the transit-amplifying (TA) zone in SI crypts of HFHSD-fed FVF mice (Fig. 4e,f). To directly assess the number of proliferating ISCs we put *Lgr5*-ki mice<sup>33</sup> on an HFHSD (Extended Data Fig. 8c). In contrast to our scRNA-seq data, we found no difference in the numbers of ISCs between CD and HFHSD by flow cytometry on the basis of high *Lgr5*-EGFP fluorescence intensity (Extended Data Fig. 8d and Fig. 4g). However, the numbers of EdU-positive ISCs were increased on HFHSD (Fig. 4h,i).

Further, we determined antigen immunoreactivity to Ki67 and the migration rate of crypt cells. We observed that Ki67-labeled domains were significantly larger in mice fed an HFHSD and, in contrast to controls, extended into the villi. Also, the crypt-to-villus migration rate of pulse-labeled 5-bromo-2'-deoxyuridine (BrdU)-positive cells was increased on HFHSD (Extended Data Fig. 8e-i) which altogether suggests that an HFHSD enhances cell turnover.

In summary, these data demonstrate that an obesogenic diet increases the proliferation rate of ISCs and progenitors leading to increased villus length. Enhanced cell-cycle activity of ISCs did not result in physical expansion of the ISC pool due to accelerated differentiation and cell turnover. This is reflected by the decreased fraction of ISCs and increased fraction of progenitors in our crypt scRNA-seq data (Fig. 1e). These results further indicate that ISC homeostasis and identity is disturbed in HFHSD-fed animals.

#### HFHSD upregulates fatty acid synthesis and *Ppar* signalling.

A central role of metabolic pathways in the regulation of stem cell maintenance and fate control has been described in several adult stem cell systems<sup>34,35</sup>. Both Wnt/ $\beta$ -catenin and *Igf1*/insulin signalling integrate metabolic and proliferative cues, and increased

activity of these pathways has been shown to induce ISC hyperproliferation upon high-fat diet (HFD) feeding<sup>6,36–38</sup>. We assessed Wnt/ $\beta$ -catenin pathway activation in bulk ISC-enriched FVF<sup>low</sup> cells and FVF<sup>neg</sup> enterocyte progenitors, which we isolated by flow cytometry (Supplementary Fig. 2a,b). Unexpectedly, the level of nuclear  $\beta$ -catenin was decreased or unchanged in ISC-enriched FVF<sup>low</sup> cells or enterocyte progenitor-enriched FVF<sup>neg</sup> cells, respectively (Supplementary Fig. 2c,d). Consistently, expression of Wnt/ $\beta$ -catenin target genes was downregulated in ISC-enriched FVF<sup>low</sup> cells and HFHSD-derived single-cell ISCs (Supplementary Fig. 2e–g and Supplementary Table 1). As glycogen synthase kinase 3 $\beta$  (Gsk3 $\beta$ ) is a negative regulator of Wnt/ $\beta$ -catenin signalling and an important modulator of cellular metabolism, we checked Gsk3 $\beta$  activity<sup>39</sup>. Decreased levels of phosphorylated Gsk3 $\beta$  in HFHSD-derived SI crypts indicated increased Gsk3 $\beta$  activity and enhanced Gsk3 $\beta$ -mediated destruction of  $\beta$ -catenin (Supplementary Fig. 2h,i). Together, these results demonstrate that Wnt/ $\beta$ -catenin signalling does not drive hyperproliferation of ISCs and progenitors and enhanced progenitor recruitment in our HFHSD mouse model. Instead, decreased Wnt/ $\beta$ -catenin signalling indicates that differentiation of ISCs is accelerated and thus provides further evidence of disturbed ISC homeostasis<sup>40,41</sup>. HFHSD caused obesity and hyperinsulinaemia in our mouse model. Analysis of *Insr**Igf1r*Akt pathway activity in SI crypt lysates showed increased phosphorylation of *Insr**Igf1r* and Akt as well as upregulation of several genes associated with PI3K and Akt signalling, which is in line with pronounced hyperinsulinaemia and confirms previous findings that *Igf1*insulin signalling induces hyperproliferation in diet-induced obesity (Extended Data Figs. 1r–u and 9a–c).


To uncover additional metabolic pathways that link HFHSD to hyperproliferation and cell fate changes, we compared metabolite profiles from SI crypt regions of CD- and HFHSD-fed FVF mice using matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI)<sup>42</sup>. MALDI-MSI allows analysis of metabolites directly in tissue sections without isolation bias. We identified 297 discriminative masses; of these, 257 were enriched and 40 were less abundant in SI crypts of HFHSD-fed animals (Fig. 5a). Pathway enrichment analysis revealed that HFHSD upregulated metabolite signatures related to fatty acid biosynthesis (for example, octadecanoic acid) and linoleic acid metabolism (for example, phosphatidylcholine) and downregulated metabolites linked to pathways of glucose metabolism, such as the pentose phosphate pathway and pentose glucuronate interconversions (for example, D-glyceraldehyde 3-phosphate) (Fig. 5b and Supplementary Table 6). To map the metabolic changes from tissue to cell-type level, we integrated metabolomics data with bulk transcriptomes of ISC-enriched FVF<sup>low</sup> cells, secretory progenitor-enriched FVF<sup>high</sup> cells and enterocyte progenitor-enriched FVF<sup>neg</sup> cells (Extended

**Fig. 4 | HFHSD induces hyperproliferation of ISCs and progenitors.** **a**, Distribution of cycling cells across CD- and HFHSD-derived cell clusters depicted as cell densities projected onto the UMAP plot and quantified as proportions of cells in each cell-cycle stage. Cells were classified using a cell-cycle score, calculated using the expression of genes related to cell cycle. Data are mean  $\pm$  s.e.m. of biologically independent samples,  $n = 3$  mice per group. **b**, Distribution of ISCs and progenitors over the three cell-cycle stages visualized as cell densities in a scatter-plot of S- versus G2/M-phase score levels. Higher score levels indicate higher expression of involved genes. Dotted lines depict classification borders. Densities are Gaussian kernel estimates. **c**, Proportions of cycling cells in CD and HFHSD-derived ISCs and progenitor clusters. Table indicates percentages. Data are shown as mean  $\pm$  s.e.m. of biologically independent samples,  $n = 3$  mice per group. EP, enterocyte progenitor; GP, goblet progenitor. **d**, Heatmap of mean expression values per cluster of selected genes used for cell-cycle scoring (black) or highly correlating with S and G2M scores (grey, Pearson correlation  $> 0.7$ ). Only cells classified as cycling (S or G2M phase) are shown. \* Indicates differentially expressed genes between CD and HFHSD conditions (two-sided, limma, adjusted  $P < 0.01$ ,  $\log_{FC} > 0.1$ ),  $n = 3$  mice per group. FC, fold change. *P* values are provided in Supplementary Table 5. **e, f**, Representative LSM images (**e**) and quantification (**f**) of EdU incorporation after a 2-h EdU (white) pulse in the TA zone in duodenal sections of CD- and HFHSD FVF mice. *Lyz1*<sup>+</sup> Paneth cells are shown in red. Scale bar, 25  $\mu$ m,  $n = 4$  mice per group. Data are mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test. FDR, false discovery rate. **g**, Determination of *Lgr5*-EGFP<sup>hi</sup> cells from CD- and HFHSD-fed *Lgr5*-ki mice by flow cytometry,  $n = 4$  mice per group. Data are mean  $\pm$  s.e.m. of biologically independent samples. **h, i**, Representative LSM images from cytospin (**h**) and quantification (**i**) of EdU<sup>+</sup>*Lgr5*-EGFP<sup>hi</sup> cells from CD- and HFHSD-fed *Lgr5*-ki mice after a 2-h EdU (white) pulse. Scale bar, 40  $\mu$ m,  $n = 4$  CD mice,  $n = 3$  HFHSD mice. Data are mean  $\pm$  s.d. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test.



Data Fig. 9d, Fig. 5c and Methods). The HFHSD metabolite signature overlapped with regulated genes involved in carbohydrate metabolism (for example, sucrose degradation, maturity onset diabetes of young (MODY) signalling) and pro-proliferative fatty acid biosynthesis pathways (for example, stearate synthesis

and acyl-CoA-hydrolysis)<sup>43</sup>. Regulation of these pathways was most pronounced in enterocyte progenitor-enriched FVF<sup>neg</sup> and ISC-enriched FVF<sup>low</sup> cells (Fig. 5d and Supplementary Table 7). Next, to determine the cell subtypes in which an HFHSD altered metabolism and to identify the molecular pathways associated with



deregulated HFHSD metabolites, we compared the transcriptional profiles of CD- and HFHSD-derived cells. We found that gene signatures associated with Ppar signalling (for example *Hmgcs2*, *Acdvl*, *Acaa2*, *Fabp1* and *Fabp2*) and fatty acid biosynthesis (for example *Acot1*, *Acox1*, *Scd2*, *Srebp1*, *Fads1* and *Me1*) were upregulated in HFHSD-derived ISC and progenitor clusters (Fig. 5e–g and Supplementary Tables 1, 8 and 9). Upregulation of these gene sets was stronger in subpopulations with proximal identity; in particular, in proximal ISCs, enterocyte and goblet progenitors (Fig. 5e,f and Supplementary Table 8). Moreover, genes associated with carbohydrate metabolism (for example glycolysis, gluconeogenesis and the pentose phosphate pathway) were downregulated in these subtypes (Fig. 5e–g). We confirmed upregulation of active *Srebp1* (mature, m-*Srebp1*), *Acc*, *Pparγ* and *Scd1*, the master transcriptional regulators and key enzymes of Ppar signalling and fatty acid synthesis in HFHSD crypt protein lysates and in ISCs and progenitors, by a sensitive, targeted single-cell qPCR approach (Fig. 5h,i, Extended Data Fig. 10 and Supplementary Table 10). Finally, consistent with crypt enterocytes, we also found that mature villus enterocytes increase the expression of genes associated with intracellular fat accumulation and lipid uptake, de novo lipogenesis and peroxisomal fatty acid oxidation (Supplementary Fig. 3).

Thus, by integration of in situ metabolomics, bulk and single-cell transcriptomics and targeted protein expression analysis, we have revealed diet-induced metabolic rewiring and cell- and subtype-specific transcriptional changes that correlate with an increase in proliferation and endocrine dysfunction.

## Discussion

In this study we provide a basic mechanistic explanation of diet-induced ISC dysfunction and intestinal maladaptation that underlie the development of obesity and prediabetes and increase the risk for gastrointestinal cancer.

With our study we aimed to determine the immediate effects of a western-style HFHSD on intestinal function. We observed enlargement of the SI, longer villi and decreased crypt density and an altered cellular composition in the crypts, which was confirmed in the villi by lineage-tracing studies. We are aware that our lineage-tracing approach using the dual-fluorescent, inducible Cre-reporter *Foxa2*<sup>mEGFP-CreERT2/+</sup>; *Gt(ROSA)2<sup>mtmG</sup>/+* mouse has its limitations; for example, inefficient labelling of stem cells, which generates fewer clonal ribbons in comparison to the *Lgr5*-ki reporter<sup>33</sup> and analysis of only one time point. Therefore, we validated our findings from the crypt scRNA-seq experiment not only by a lineage-tracing approach but also independent of a reporter in tissue sections.

We show that ISCs and progenitors are hyperproliferative, and that differentiation and cell turnover are accelerated by an HFHSD.

Accelerated differentiation and cell turnover also explain the discrepancy between the scRNA-seq data (decrease in ISCs) and the data from the *Lgr5*-reporter mice (no change in the number of ISCs). ISCs in HFHSD-fed mice divide faster and newly formed cells are still *Lgr5*-EGFP<sup>hi</sup>, but already express markers of differentiated cells. Whole-transcriptome-based clustering in our scRNA-seq data groups *Lgr5*<sup>hi</sup> ISCs and *Lgr5*<sup>hi</sup> progenitors separately, whereas when using only *Lgr5*-EGFP as a marker in tissue sections and flow cytometry we cannot discriminate between an ISC and a progenitor.


Hyperproliferation in the crypt, which can promote cancer initiation and progression, has previously been associated with an HFD; however, the molecular pathways that couple dietary cues to this cellular response are still debated and probably depend on the type of diet (for example fat and sugar source)<sup>37,38,44</sup>. Also, a role of metabolic pathways in ISC maintenance, number and fate control has been highlighted in several studies<sup>7,44,45</sup>. Hyperproliferation upon HFHSD is not driven by *Pparδ*-mediated activation of the major oncogenic pathway in the gut, Wnt/β-catenin signalling, as previously reported for a lard-based chronic HFD<sup>6,46,47</sup>. Instead, we found that a coconut oil- and sucrose-based high-lipid and -carbohydrate content diet specifically elevates pro-proliferative *Pparγ* signalling, *Srebp1*-mediated lipogenesis and *Insrlgfr*-Akt signalling. Upregulation of *Pparγ* and *Srebp1*-mediated de novo lipogenesis has been associated with inflammation, increased proliferation and tumour progression in many types of cancer and thus provides a possible link between HFHSD-induced metabolic signalling, crypt-cell hyperproliferation and increased risk of gastrointestinal cancer<sup>43</sup>. As tumour initiation and progression require biomass production and therefore depend on a high nutrient supply, chronic activation of these pathways as observed with an HFHSD might reduce the barrier to oncogenic transformation or tumour growth and proliferation.

Further, we found a profound impact of an HFHSD on the enterocyte lineage. Enterocytes are metabolically rewired, increase the expression of genes linked to carbohydrate and fat uptake and show an intracellular fat accumulation, which is reminiscent of the vesicular accumulation of triglycerides in hepatic steatosis that causes liver fibrosis and cancer<sup>48–50</sup>. In addition, HFHSD induces a regional and spatial repatterning of enterocyte gene expression and function. An HFHSD increased the number of proximal-type enterocytes, which are specialized on carbohydrate and fatty acid absorption and altered enterocyte zonation along the crypt–villus axis (increased expression of the fatty acid transporter *Fabp1*). Thus, our results imply that enterocytes functionally adapt to an HFHSD, which may increase calorie intake and fat accumulation and promote obesity.

**Fig. 5 | Fatty acid synthesis and Ppar signalling are upregulated on HFHSD.** **a**, Heatmap-based clustering analysis of the 297 discriminative metabolite masses ( $FC \geq 2$  and  $P \leq 0.05$ ). Each coloured cell on the map corresponds to an intensity value, with samples in rows and features in columns. Euclidean distance and Ward's method were applied for clustering analysis. Statistical significance was determined by two-tailed Student's *t*-test. **b**, Pathway enrichment analysis of deregulated metabolites was performed with MetaboAnalyst 3.0. The enrichment method was hypergeometric test. Topology analysis was based on relative betweenness centrality. The *P* value was calculated from the enrichment analysis without adjustment ( $FC \geq 2$  and  $P \leq 0.05$ ). Metabolic pathways are represented as circles according to their scores from enrichment (vertical axis) and topology analyses (pathway impact, horizontal axis). **c**, Overview of experimental design for data integration. **d**, Ingenuity pathway analysis showing overlap of significantly deregulated metabolites on HFHSD from MALDI-MSI profiling and genes from microarray analysis. Shown are values from microarray analysis and the red line indicates the significance cutoff. **e**, Enriched KEGG pathways in genes differentially regulated between CD and HFHSD conditions (Enrichr, Fisher's exact test, two-sided). Genes with  $FDR < 0.01$  and  $\log FC > 0.1$  were considered and weighted by  $\log FC$ . **f**, Volcano plots showing differential expression and its significance ( $-\log_{10}(FDR)$ , limma) for each gene on HFHSD compared to CD. Red lines indicate thresholds used for significance level and gene expression change and regulated genes are highlighted in black. Annotated genes are the top ten genes ranked by FDR. **g**, Mean expression levels for selected genes. \* Indicates a significant change (limma,  $FDR < 0.01$ ,  $\log FC > 0.1$ ). **h,i**, Protein expression analysis by western blot in cytoplasmic (cyto) and nuclear (nucl) extracts from SI crypts of CD- and HFHSD-fed FVF mice. Representative immunoblots (**h**) and relative quantification of band signal intensity (**i**),  $n = 4$  mice per group (*Srebp1*, *Scd1*, *Acc*, *Fasn*) and  $n = 7$  mice per group (*Pparγ*). Data are presented as box-and-whisker plots. The lower and upper boundaries of the boxes represent the 25th and 75th percentiles, respectively. The centre lines indicate the medians and whiskers represent the maximum and minimum values. Statistical significance was determined by two-tailed Student's *t*-test. Circles represent biological independent samples. norm., normalized.

Our in-depth molecular and functional analysis of the EEC lineage reveals mechanisms of EEC dysfunction in obesity that include (1) higher abundance of *Ngn3*<sup>+</sup> EEPs owing to increased

proliferation, (2) lower abundance of serotonergic *Reg4*<sup>+</sup> EC cells and lower plasma serotonin levels, (3) higher abundance of peptide-ergic *Ghr1*<sup>+</sup> SILA cells but lower ghrelin plasma levels, (4) increased



numbers of ileal Gcg<sup>+</sup> cells and increased Glp-1 levels and (5) lower abundance of *Lgr5*<sup>+</sup> EECs. The physiological roles of gut-derived serotonin are broad and it regulates various processes both in the gut and systemically<sup>32</sup>. Accumulating evidence indicates a link between peripheral serotonin and systemic glucose and lipid metabolism, as well as metabolic diseases<sup>51</sup>. Whether blood serotonin levels are changed in obesity is controversial, due to difficulties in measuring serotonin<sup>51</sup>. However, intraperitoneal injection of 5-HT to mice inhibits weight gain, hyperglycaemia and insulin resistance on an HFD<sup>52</sup>. Thus, reduced numbers of serotonin-producing cells and blood serotonin levels as observed in our mouse model might promote the development of obesity. The hunger hormone ghrelin is known to increase gastric emptying and decrease insulin secretion<sup>53</sup>. A negative correlation between plasma insulin and ghrelin has been reported in human obesity, which is in line with our data<sup>54</sup>. Notably, we found that lower plasma ghrelin levels are not due to a reduced number of Ghrl<sup>+</sup> SILA cells, suggesting that an impaired secretory machinery might affect ghrelin levels. However, given that ghrelin-secreting cells are also present in the stomach, changes in plasma ghrelin levels may not be solely attributed to duodenal Ghrl<sup>+</sup> EECs. Lower postprandial GLP-1 levels are reported in obesity and incretin hormone secretion and activity are impaired in individuals with prediabetes, although findings are contradictory<sup>9,55</sup>. In our obesity model, however, the number of Gcg-expressing cells and Glp-1 plasma levels were increased. Glp-1 stimulates insulin secretion from pancreatic  $\beta$ -cells, so the higher levels of circulating Glp-1 in HFHSD-fed mice may be a compensatory response to insulin resistance at the prediabetic state, which leads to hyperinsulinaemia.

Finally, in contrast to other studies, Paneth cell numbers were not affected in our obesity model<sup>6</sup>.

The discrepancies between our results and those of previous studies support the emerging evidence that the intestine fine-tunes its response to environmental stimuli<sup>6,37,38</sup>. Different factors, such as the selected mouse model (for example, diet versus genetically induced obesity), type of diet (for example HFD versus HFHSD), fat source (for example lard versus coconut oil) and/or duration of diet (short-term versus chronic) can influence intestinal remodelling and response. For instance, in contrast to the coconut oil, high-sucrose diet for 12–14 weeks used in this study, a lard-based low-sugar chronic diet for 9–14 months caused shorter villi, increased the number of ISCs, decreased the number of Paneth cells and did not affect goblet cells and EECs<sup>6</sup>. Hence, careful selection and reporting of dietary information in animal studies is crucial to interpret and contextualize results.

In summary, our study reveals that functional maladaptation of the gut in response to an HFHSD is caused by disturbed ISC identity, changes in the regional identity of cells and an altered mature cell-type composition. Further, we describe targetable pathways that are induced by an HFHSD and potentially underlie the pathogenesis of the metabolic syndrome and gastrointestinal cancer. This new understanding of the mechanisms of disease is crucial to develop non-invasive therapeutic options to resolve obesity and insulin-dependent diabetes, for example by counteracting enteroendocrine dysregulation (for example, by elevating peripheral serotonin levels) and increased nutrient absorption (for example, by inducing distal enterocyte phenotypes).

## Methods

**Experimental model. Animals.** Animal experiments were carried out in compliance with the German Animal Protection Act and with the approved guidelines of the Society of Laboratory Animals and of the Federation of Laboratory Animal Science Associations. This study was approved by the institutional Animal Welfare Officer (Helmholtz Center Munich) and by the Government of Upper Bavaria, Germany. Homozygous FVF mice were generated as previously described and backcrossed to C57BL/6 background<sup>22</sup>. *Foxa2*<sup>EGFP-CreERT2</sup> mice<sup>25</sup> (CD1 background) were crossed with *Gt(ROSA)26<sup>mTmG</sup>* mice<sup>24</sup> (mixed 129/SvJ, C57BL/6J background) to obtain heterozygous *Fo*

*x2*<sup>EGFP-CreERT2</sup>;*Gt(ROSA)26<sup>mTmG</sup>* animals and bred in our own facilities.

Other mouse lines were *Lgr5-EGFP-IRES-creERT2* (ref. <sup>33</sup>) (*Lgr5*-ki, C57BL/6J background) and wild-type C57BL/6N (bred in our own facilities).

Mice were housed in groups of two to four animals and maintained at 23 ± 1 °C and 45–65% humidity on a 12-h dark/light cycle with ad libitum access to diet and water unless otherwise indicated. All experiments were performed using male animals at 3 to 7 months of age.

**Dietary interventions.** For dietary interventions, 10–12-week-old male mice were randomized into test groups matched for body weight, with similar variance, and given ad libitum access to either an obesogenic HFHSD (58% kcal from fat, 25% kcal from carbohydrates, 17% kcal from protein (Research Diets, no. D12331)) or CD (11% kcal from fat, 64% kcal from carbohydrates, 25% kcal from protein (ssniff Spezialdiäten, E15051-04)) for a period of 11–13 weeks. Body weights were measured every second week.

**Body composition analysis.** Lean and fat masses were measured in FVF mice 12 weeks after the start of the diet using quantitative nuclear magnetic resonance technology (EchoMRI).

**Glucose tolerance and insulin secretion tests.** Glucose tolerance was assessed by an oral glucose tolerance test (oGTT) in FVF mice, maintained for 12 weeks on CD or HFHSD. After a 6-h fast, mice received an oral glucose bolus (1.5 mg g<sup>-1</sup> body weight of 20% (wt/v) D-(+)-glucose (Sigma-Aldrich) in PBS). Tail blood glucose concentrations were measured with a handheld glucometer (Abbott) before (0 min) and 15, 30, 60 and 120 min after the glucose bolus. To measure the insulin secretion, tail vein blood samples were collected into EDTA-coated microvette tubes (SARSTEDT) at time points 0, 15 and 30 min of the oGTT. Plasma was extracted by centrifugation (3,500 r.p.m., 15 min, 4 °C) and insulin concentration was determined using the Ultra-Sensitive Mouse Insulin ELISA Kit (Crystal Chem, 90080) according to the manufacturer's instructions.

The homeostasis model assessment of insulin resistance (HOMA-IR) and HOMA- $\beta$  were used to assess insulin resistance and beta-cell function, respectively, in FVF mice at 12 weeks after diet start. HOMA indices were calculated from basal blood glucose and plasma insulin levels after a 6-h fast based on the conventional formulas: HOMA-IR = fasting blood glucose (mg per 100 ml) × fasting insulin ( $\mu$ U per ml)/405 and HOMA- $\beta$  = fasting insulin ( $\mu$ U per ml) × 360/fasting glucose (mg per 100 ml) – 63 (ref. <sup>56</sup>).

**Plasma hormone measurements.** Circulating hormones, serotonin, ghrelin and Glp-1 were assessed in FVF mice maintained for 13 weeks on a CD or an HFHSD. For basal levels (ghrelin and serotonin), mice were fasted for 6 h and tail vein blood was sampled into EDTA-coated microvette tubes (SARSTEDT). To compare postprandial plasma hormone levels (Glp-1, ghrelin), fasted mice were gavaged with 250  $\mu$ l of mixed-meal-containing liquid diet (Osmolite HiCal, Abbott) supplemented with dextrose at 20% (wt/v) (Sigma-Aldrich). Blood was collected 10 min after the mixed-meal bolus either from the tail vein or, under terminal anaesthesia with isoflurane, from the vena cava<sup>57–59</sup>. For Glp-1 measurement, blood samples were immediately mixed with 0.1 mM Diprotin A (Abcam, 145599) and 500 KIU ml<sup>-1</sup> aprotinin (Sigma, A-1153). Plasma was extracted by centrifugation (13,000 r.p.m., 2 min, 4 °C). Total ghrelin concentrations were determined using an ELISA kit from Millipore-Merck (EZRGRT-91K), total plasma Glp-1 was measured using a mouse Glp-1 ELISA kit (Crystal Chem, 81508) and serotonin concentration was determined using a serotonin ELISA kit from Enzo (ADI-900-175).

## Proliferative cell labelling with EdU and BrdU and tamoxifen administration in mice

To assess the epithelial replication rate in the SI, EdU (Thermo Fisher Scientific, A10044) or BrdU (Sigma, no. B5002) was administered as an intraperitoneal injection at 100  $\mu$ g g<sup>-1</sup> body weight or at 50  $\mu$ g g<sup>-1</sup> body weight, respectively, each from a 10 mg ml<sup>-1</sup> stock and in sterile PBS. Mice were killed 2 h post-EdU or 24 h post-BrdU administration. For the assessment of BrdU label retention, FVF mice maintained for 10 weeks on a diet were given BrdU in drinking water at 1 mg ml<sup>-1</sup> supplemented with 1% sucrose for 14 d. BrdU was then withdrawn and mice were further maintained on a diet with ad libitum drinking water for a chase period of 21 d. A group of mice was killed after 14 d of continuous BrdU labelling or after a 21 d period of chase. For short-term genetic lineage studies, *Foxa2*<sup>EGFP-CreERT2</sup>;*Gt(ROSA)26<sup>mTmG</sup>* mice were fasted for 3 h and Cre-recombinase activity was induced by a titrated single dose of tamoxifen administered orally by gavage (Sigma-Aldrich, T5648) at 0.25 mg g<sup>-1</sup> body weight in sunflower oil. Mice were killed 70 h after the tamoxifen gavage.

**Crypt and villus isolation and single-cell preparation.** Isolation of small intestinal crypts was carried out as previously reported<sup>40</sup>. In brief, SIs were removed and washed with cold PBS. Villi were scraped off with a glass slide. The remaining tissue was cut into 2-cm pieces, washed several times with cold PBS and incubated in 2 mM EDTA/PBS for 35 min at 4 °C on a tube roller. Subsequently, crypts were collected by rigorous shaking and filtered through a 70- $\mu$ m mesh to remove villous fragments. For single-cell preparation, isolated crypts were incubated with TrypLE (Life Technologies, no. 12605) for 5 min on ice and then 5 min at 37 °C and treated



with  $10 \mu\text{g ml}^{-1}$  DNase in crypt complete medium (DMEM/F-12 containing 10% FCS) for 5 min at  $37^\circ\text{C}$ . Single-cell suspension was achieved by gentle repeated pipetting. Cells were washed twice with 2% FCS in PBS and pelleted at 300g for 5 min at  $4^\circ\text{C}$ . For flow cytometry, cells were collected in 1–2 ml FACS buffer (2% FCS, 2 mM EDTA in PBS) (Sigma-Aldrich, no. Y0503) and passed through 40- $\mu\text{m}$  cell strainer caps of FACS tubes.

To obtain a single-cell suspension of villi cells, villi were scraped off and incubated with TrypLE as described for crypt cells.

**Flow cytometry.** For gene expression measurement (microarray, single-cell transcriptomics) and western blotting, small intestinal crypt cells were sorted using FACS-Aria III (FACSDiva software v.6.1.3, BD Bioscience) with a 100- $\mu\text{m}$  nozzle. For all experiments, single cells were gated according to their FSC-A (front scatter area) and SSC-A (side scatter area). Singlets were gated dependent on the FSC-W (front scatter width) and FSC-H (front scatter height) and dead cells were excluded using 7-AAD (eBioscience, no. 00-6993-50). For quantitative PCR with reverse transcription (qRT-PCR), cells were sorted directly into Qiazol lysis reagent (QIAGEN, no. 79306). To obtain FVF-enriched small intestinal crypt-cell samples for scRNA-seq, we sorted 30,000 FVF<sup>+</sup> (FVF<sup>low</sup> and FVF<sup>high</sup>) cells followed by sorting 30,000 live crypt cells per sample. Cells were sorted into modified FACS buffer (2% FCS, 0.02 mM EDTA in PBS).

**RNA isolation for qRT-PCR and microarray.** For bulk gene profiling studies (qPCR, microarray), RNA isolation from crypts or flow-sorted cells was performed using the RNA isolation kit miRNeasy Mini (QIAGEN, no. 217004) or miRNeasy Micro kit (QIAGEN, no. 217084) depending on the amount of the sample. Complementary DNA was synthesized using the SuperScript VILO cDNA synthesis kit (Invitrogen, no. 11754). RNA was reverse transcribed and amplified with the Ovation PicoSL WTA System V2 kit (NuGEN, no. 331248).

**Microarray analysis.** For gene profiling of flow-sorted FVF<sup>low</sup>, FVF<sup>high</sup> and FVF<sup>neg</sup> cells from CD- and HFHSD-fed FVF mice, total RNA was isolated as described above and RNA integrity was assessed using an Agilent 2100 Bioanalyzer (Agilent RNA 6000 Pico Kit). RNA was amplified with the Ovation PicoSL WTA System V2 in combination with the Encore Biotin Module (NuGen). Amplified cDNA was hybridized on Affymetrix Mouse Gene 1.0 ST arrays. Staining (Fluidics script FS450\_0007) and scanning of the microarray were performed according to the Affymetrix expression protocol including minor modifications as suggested in the Encore Biotin kit protocol. Expression Console (v.1.3.0.187, Affymetrix) was used for quality control and annotation of the normalized robust microarray analysis gene-level data, and standard settings, including median polish and sketch-quantile normalization, were used.

**TaqMan qRT-PCR.** For gene expression analysis, real-time qRT-PCR was performed using TaqMan probes (Life Technologies), TaqMan Fast Advanced Master Mix (Applied Biosystems, no. 4444557) or TaqMan Universal Master Mix II (Applied Biosystems, no. 4440040) for amplified cDNA and the ViiA 7 Real-Time PCR System (Thermo Fisher Scientific).

The following probes were used: Mm00782745\_s1 for *Rpl37*, Mm00438890\_m1 for *Lgr5*, Mm01320260\_m1 for *Olfm4*, Mm01268891\_g1 for *Ascl2*, Mm00443610\_m1 for *Axin2*, Mm03928990\_g1 for *RN18S*, Mm02524776\_s1 for *Fzd2*, and Mm00433409\_s1 for *Fzd7*.

**scRNA-seq: RNA preparation, library generation and sequencing.** FVF-enriched single-cell samples of crypts isolated from the small intestinal epithelium (duodenum, jejunum and ileum) and villus samples from the SI of C57BL/6N mice were prepared as described above. Dead cells were excluded by flow cytometry after 7AAD labelling. Dead cell exclusion was controlled by trypan blue staining and sorted cells were counted. Single-cell libraries were generated using the Chromium Single cell 3' library and gel bead kit v2 (10X Genomics, no. 120237) according to the manufacturer's instructions. Libraries were sequenced on a HiSeq4000 (Illumina) with 150-bp paired-end sequencing of read 2.

**MALDI-MSI.** Fresh-frozen samples were cut into 12- $\mu\text{m}$  sections using a cryo-microtome at  $-20^\circ\text{C}$  (Leica CM1950, Leica Microsystems) and mounted onto precooled conductive indium-tin-oxide-coated MALDI target glass slides (Bruker Daltonics). Sections were coated with 9-aminoacridine hydrochloride monohydrate matrix (Sigma-Aldrich) at  $10 \text{ mg ml}^{-1}$  in water/methanol 30:70 (v/v) by a SunCollect automatic sprayer (Sunchrom). The matrix application was performed at flow rates of 10, 20 and 30, respectively, for the first three layers. The other five layers were performed at  $40 \mu\text{l min}^{-1}$ . MALDI-MSI measurement was performed on a Bruker Solarix 7T FT-ICR-MS (Bruker Daltonics). MALDI-MSI data were acquired over a mass range of  $m/z$  50–1,000 in negative ionization mode with 30- $\mu\text{m}$  spatial resolution using 50 laser shots at a frequency of 500 Hz. The acquired data underwent spectrum processing in FlexImaging v4.2 (Bruker Daltonics). Following MALDI imaging experiments, the matrix was removed with 70% ethanol. Tissue sections were stained with haematoxylin and eosin. Slides were scanned with a MIRAX DESK digital slide-scanning system (Carl Zeiss MicroImaging).

**Western blot.** For protein expression analyses, whole-cell lysates from isolated crypts or flow-sorted cells were prepared using the RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Igepal, 0.1% SDS, 0.5% sodium deoxycholate) containing phosphatase (Sigma-Aldrich, P5726, P0044) and proteinase inhibitors (Sigma-Aldrich, P8340). Nuclear and cytosolic extracts from isolated crypts were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Reagents kit (Thermo Fisher Scientific, no. 78833) according to the manufacturer's instructions. Cell lysates were mixed with Laemmli sample buffer, resolved by SDS-PAGE and blotted onto a PVDF membrane (Bio-Rad). Membranes were blocked with 5% milk in Tris-buffered saline containing 0.2% Tween-20, then incubated overnight with primary antibodies in blocking solution at  $4^\circ\text{C}$ , followed by a 1-h incubation with horseradish peroxidase (HRP)-conjugated IgG secondary antibodies. Protein bands were visualized using a chemiluminescence reagent (Bio-Rad, no. 170-5061) and quantified using ImageJ software. For quantification, expression of proteins was normalized to  $\alpha$ -tubulin or lamin in cytoplasmic or nuclear fractions, respectively.

Primary antibodies used were mouse anti-Srebp1 (1:1,000 dilution, Novus Biologicals, NB600-582S); rabbit anti-Acc (1:1,000 dilution, Cell Signaling Technology, 3676); rabbit anti-Ppary (1:1,000 dilution, Cell Signaling Technology, 2435); goat anti-lamin (1:1,000 dilution, Santa Cruz, sc-6217); mouse anti- $\alpha$ -tubulin (1:1,000 dilution, Sigma-Aldrich, T6199); rabbit anti-Fasn (1:1,000 dilution, Cell Signaling Technology, 3180); rabbit anti-Scd1 (1:1,000 dilution, Cell Signaling Technology, 2794); mouse anti- $\beta$ -catenin (1:1,000 dilution, BD, 610154); rabbit anti-Gsk3 $\beta$  (1:5,000 dilution, Cell Signaling Technology, 12456); and rabbit anti-phospho Gsk3 $\beta$  (1:5,000 dilution, Cell Signaling Technology, 5558). Secondary antibodies used were goat anti-mouse HRP (1:15,000 dilution, Dianova, 115036062); goat anti-rabbit HRP (1:15,000 dilution, Dianova, 111036045) or rabbit anti-goat HRP (1:15,000 dilution, Dianova, 305035045).

**Tissue morphology assessment.** For tissue histology, intestines were flushed and fixed in 4% paraformaldehyde (PFA) overnight, paraffin embedded according to standard procedures and sectioned at 6  $\mu\text{m}$ . Sections were dried, dehydrated through a graded ethanol series and cleared in xylene. Standard haematoxylin and eosin staining was performed and images were acquired using the Zeiss AXIO Scope A1 microscope (Carl Zeiss AG).

**Histochemistry and immunofluorescence.** SIs were isolated, rinsed with ice-cold PBS and fixed with 4% PFA for 3 h at  $4^\circ\text{C}$ . Tissue was cryopreserved through a progressive sucrose gradient (7.5% for 1 h, 15% for 1 h, 30% sucrose overnight), embedded in a tissue-freezing medium (Leica Biosystems, no. 14020108926) and sectioned at 14  $\mu\text{m}$ . For whole-mount staining, isolated small intestinal crypts were fixed in 4% PFA for 30 min at room temperature (RT) and subsequently washed in PBS. For immunofluorescence staining, sections or crypts were permeabilized with 0.5% Triton X-100 in PBS for 30 min at RT, blocked (10% FCS, 0.1% BSA and 3% donkey serum in PBS/0.1% Tween-20) for 1 h and incubated with primary antibodies overnight at  $4^\circ\text{C}$ . Sections or crypts were washed in PBS/0.1% Tween-20 and incubated with secondary antibodies in blocking solution for 1 h at RT, stained with DAPI (ROTH, 6335.1) to visualize the nuclei and mounted with the Elvanol antifade reagent.

To assess proliferation, EdU staining was performed using the Click-iT Staining kit (Invitrogen, no. C10340) according to the manufacturer's instructions.

For BrdU staining, sections were incubated with 3.3 N HCl for 10 min on ice, followed by incubation for 50 min at  $37^\circ\text{C}$  and two wash steps with borate buffer, pH 8.5, to neutralize the reaction (each wash 15 min at RT).

Ki67 immunoreactivity was assessed on paraffin tissue sections after heat-induced antigen retrieval (at  $\sim 90^\circ\text{C}$ , 10 min) using the Antigen Unmasking Solution, Citric Acid-Based (Vector Laboratories, no. H-3300-250).

Fluorescent images were obtained with a Leica SP5 confocal microscope (Leica Microsystems) and analysed using LAS AF software (LAS AF software v.2.6.0-7266).

The primary antibodies used were chicken anti-GFP (1:600 dilution, Aves Labs, GFP-1020); goat anti-ChgA (1:200 dilution, Santa Cruz, sc-1488); rabbit anti-Lyz1 (1:1,000 dilution, DAKO, M0776); rabbit anti-Muc2 (1:1,000 dilution, Santa Cruz, sc-7314); rat anti-BrdU (1:200 dilution, Abcam, ab6326); rabbit anti-5-HT (1:1,000 dilution, Neuromics, RA20080); anti-rabbit Ngn3 (1:100 dilution, a kind gift from H. Edlund); goat anti-villin (1:200 dilution, Santa Cruz, sc-7672); goat anti-ghrelin (1:200 dilution, Santa Cruz, sc-10368); rabbit anti-Ki67 (1:200 dilution, Abcam, ab15580); rabbit anti-E-cadherin (extracellular domain) (1:1,000 dilution, a gift from D. Vestweber); rabbit anti-Fabp1 (1:300 dilution, Abcam, ab222517); and rabbit anti-ApoA4 (1:300 dilution, Abcam, ab231660). The secondary antibodies used were donkey anti-chicken Alexa Fluor 488 (1:800 dilution, Dianova, 703225155); donkey anti-mouse Cy5 (1:800 dilution, Dianova, 715175151); donkey anti-goat Alexa Fluor 555 (1:800 dilution, Invitrogen, A21432); donkey anti-rabbit Alexa Fluor 555 (1:800 dilution, Invitrogen, A31572); and donkey anti-rabbit Alexa Fluor 649 (1:800 dilution, Dianova, 711605152).

**RNAscope in situ hybridization for detection of target RNA.** In situ detection of *FOXA2*, *LGR5* and *OLFM4* mRNA was performed using the RNAscope Intro Pack for Multiplex Fluorescent Reagent Kit v2-Mm (ACD; no. 323136) according to the

manufacturer's protocol. RNAscope 3-Plex Negative Control Probe (dapB; ACD; no. 320871) and RNAscope 3-Plex Positive Control Probe (ACD; no. 320881) were used as internal controls. Probes used were Mm-Foxa2 (ACD; no. 409111), Mm-Olfm4-C2 (ACD; no. 311831-C2) and Mm-Lgr5-C3 (ACD; no. 312171-C3) with respective fluorescent dyes Opal 520 Reagent (AKOYA; no. FP1487001KT) for channel 1, Opal 570 Reagent (AKOYA; no. FP1488001KT) for channel 2 and Opal 690 Reagent (AKOYA; no. FP1497001KT) for channel 3, diluted 1:800 in RNAscope Multiplex TSA Buffer (ACD; no. 322809). The assay was performed on FFPE mouse intestinal jejunum sections prepared as described above with a thickness of 7 µm and standard pretreatment conditions with protease III (ACD; no. 322340) as recommended by the manufacturer.

After completion of the RNAscope assay, sections were stained using DAPI (ROTH, 6335.1) to visualize the nuclei, washed with PBS three times and mounted with ProLong Diamond Antifade Mountant (Life Technologies; no. P36970). Samples were visualized using a Leica SP5 confocal microscope (LAS AF software v.2.6.0-7266).

**Gene expression analysis from bulk sorted cells.** Statistical bulk transcriptome analyses were performed using the statistical programming environment R implemented in CARMAweb<sup>61,62</sup>. Gene-wise testing for differential expression was carried out employing the limma *t*-test. Sets of regulated genes were defined by raw  $P < 0.01$ , FC  $> 1.3\times$  and average expression in at least one group  $> 32$ . Enriched canonical pathways were analysed through the use of QIAGEN's ingenuity pathway analysis (<https://www.qiagen.com/ingenuity>). Microarray data are available at Gene Expression Omnibus (GEO).

**Bioinformatics and statistical analysis of MALDI-MSI data.** MATLAB R2014b (v.7.10.0, Mathworks) was used as MALDI spectral pre-processing tool for the subsequent data bioinformatics analysis. Peak picking was performed using an adapted version of the LIMPIC algorithm<sup>63</sup>. In brief, the parameters of peak picking included  $m/z$  0.0005 minimal peak width, signal-to-noise threshold of 4 and intensity threshold of 0.01%. Isotopes were automatically identified and excluded. Statistical comparisons were performed with a Student's *t*-test (two-tailed). Metabolites were considered to be significant if they had an intensity FC  $\geq 2$  and a  $P$  value  $\leq 0.05$ . Metabolite annotation was performed by matching accurate mass with databases (mass accuracy  $\leq 4$  ppm, METLIN, <http://metlin.scripps.edu/>; Human Metabolome Database, <http://www.hmdb.ca/>; MassTRIX, <http://masstrix3.helmholtz-muenchen.de/masstrix3/>; METASPACE, <http://annotate.metaspace2020.eu/>). Heat-map-based clustering and enrichment analysis of metabolic pathways were performed with MetaboAnalyst v.3.0 (<http://www.metaboanalyst.ca>).

**Integration of bulk transcriptome and metabolome.** Lists of genes participating in the candidate pathways from the ingenuity canonical pathways analysis of the microarray data of FVF<sup>low</sup>, FVF<sup>high</sup> and FVF<sup>neg</sup> cells were compiled. For each of the genes on the lists, information on the reaction it is involved in and the participating metabolites were extracted from the mouse specific BiGG databank (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874806/>, <https://www.ncbi.nlm.nih.gov/pubmed/20959003>). If genes and metabolites within a reaction were also significant in their analyses as described above, the reaction and its pathway were said to be affected at both the metabolomics and the transcriptomics levels.

**Single-cell gene expression analysis by microfluidic qRT-PCR.** To assess the transcriptional profiles of single FVF<sup>low</sup> and FVF<sup>high</sup> cells, a nested single-cell qPCR design was used. FVF<sup>low</sup> or FVF<sup>high</sup> cells isolated from three CD- and HFHSD-fed FVF mice were sorted as described above directly into single wells of 96-well plates containing 5 µl of a pre-amplification solution composed of 1.2 µl 5× VIL0 reaction mix (Invitrogen, no. 11754-050), 0.3 µl 20 U µl<sup>-1</sup> SUPERase-In (Ambion, no. AM2694), 0.25 µl 10% NP40 (Thermo Fisher Scientific, no. 28324), 0.25 µl RNA spikes mix (Fluidigm, no. 100-5582) and 3 µl of nuclease-free water (Promega, no. P119C). Cells were lysed by incubation at 65 °C for 90 s and cDNA transcription from RNA was performed by reverse transcription cycling (25 °C for 5 min, 50 °C for 30 min, 55 °C for 25 min, 60 °C for 5 min and 70 °C for 10 min) with 1 µl reverse transcription mix solution containing 0.15 µl 10× SuperScript enzyme mix (Invitrogen, no. 11754-050), 0.12 µl T4 Gene 32 Protein (New England BioLabs, no. M0300S) and 0.73 µl nuclease-free water. The efficiency and specificity of outer and inner primer pairs for target-specific cDNA amplification were tested in advance. Primers showing single peaks and single bands by melt curve analysis and by separation of qPCR products on a 2.5% agarose gel, respectively, were considered specific. Primer efficiency was analysed over a range of tenfold cDNA dilutions (1:1 to 1:100) and primers with 100 ± 15 % efficiency were qualified for further proceedings. Specific target amplification was performed with 9 µl reaction mix containing 7.5 µl TaqMan PreAmp Master Mix (Applied Biosystems, no. 4391128), 0.075 µl 0.5 M EDTA, pH 8.0 (Invitrogen, no. AM9260G), 1.5 µl 10× outer primer mix (500 nM) under the following cycling conditions: enzyme activation step at 95 °C for 10 min, 20 cycles of denaturation for 5 s at 96 °C and 4 min annealing/extension at 60 °C. Amplified cDNA samples were then treated with 6 µl Exonuclease I reaction mix containing 0.6 µl reaction buffer, 1.2 µl Exonuclease I (New England BioLabs, no. M0293S) and 4.2 µl nuclease-free

water. To increase target specificity, amplified single-cell cDNA samples were analysed with gene-specific inner primer pairs and SsoFast EvaGreen Supermix with Low ROX (Bio-Rad Laboratories, no. 172-5210) using the 96.96 Dynamic Array on the BioMark System (Fluidigm). BioMark Real-Time PCR Analysis software (Fluidigm) was used to calculate Ct values.

**Computational analyses of single-cell data.** A detailed description of the computational analyses of single-cell data is provided in the Supplementary information.

**Statistical analyses.** Data collection was performed using Microsoft office Excel 2016–2018 and statistical analysis was performed using GraphPad Prism 6 Software (GraphPad Software). All data are shown as mean ± s.e.m. unless otherwise specified. In box-and-whiskers plots, data are represented as minimum and maximum with centre lines indicating the median. All samples represent biological replicates. For statistical significance testing of two independent groups, an unpaired two-tailed Student's *t*-test was used. For statistical comparison of longitudinal data (body weight curves, GTT and IST), two-way analysis of variance corrected by Sidak's multiple comparison test was used.  $P$  values of  $< 0.05$  % were considered statistically significant. For metabolic studies (GTT and IST), sample size was statistically determined; otherwise sample size estimates were not used. Studies were not blinded and investigators were not blinded during analysis.

**Reporting Summary.** Further information on research design is available in the Nature Research Reporting Summary linked to this article.

## Data availability

All data generated or analysed during this study are included in this article and its supplementary files. Microarray data have been submitted to NCBI/GEO (GSE148227). scRNA-seq data have been submitted to NCBI/GEO (GSE147319). Source data are provided with this paper.

## Code availability

Code and custom scripts for scRNA-seq analysis have been deposited on [https://github.com/theislab/2021\\_Aliuev\\_Tritschler\\_gut\\_HFD](https://github.com/theislab/2021_Aliuev_Tritschler_gut_HFD).

Received: 27 March 2020; Accepted: 13 August 2021;

Published online: 22 September 2021

## References

- Schauer, P. R. et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. *N. Engl. J. Med.* **366**, 1567–1576 (2012).
- Evers, S. S., Sandoval, D. A. & Seeley, R. J. The physiology and molecular underpinnings of the effects of bariatric surgery on obesity and diabetes. *Annu. Rev. Physiol.* **79**, 313–334 (2017).
- Drucker, D. J. Mechanisms of action and therapeutic application of glucagon-like peptide-1. *Cell Metab.* **27**, 740–756 (2018).
- Gribble, F. M. & Reimann, F. Function and mechanisms of enteroendocrine cells and gut hormones in metabolism. *Nat. Rev. Endocrinol.* **15**, 226–237 (2019).
- Yilmaz, Ö. H. et al. MTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. *Nature* **486**, 490–495 (2012).
- Beyaz, S. et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. *Nature* **531**, 53–58 (2016).
- Mihaylova, M. M. et al. Fasting activates fatty acid oxidation to enhance intestinal stem cell function during homeostasis and aging. *Cell Stem Cell* **22**, 769–778 (2018).
- Le Gall, M. et al. Intestinal plasticity in response to nutrition and gastrointestinal surgery. *Nutr. Rev.* **77**, 129–143 (2019).
- Lean, M. E. J. & Malkova, D. Altered gut and adipose tissue hormones in overweight and obese individuals: cause or consequence. *Int. J. Obes.* **40**, 622–632 (2016).
- Dailey, M. J. Nutrient-induced intestinal adaption and its effect in obesity. *Physiol. Behav.* **136**, 74–78 (2014).
- Verdam, F. J. et al. Small intestinal alterations in severely obese hyperglycemic subjects. *J. Clin. Endocrinol. Metab.* **96**, E379–E383 (2011).
- Gehart, H. & Clevers, H. Tales from the crypt: new insights into intestinal stem cells. *Nat. Rev. Gastroenterol. Hepatol.* **16**, 19–34 (2019).
- Clevers, H. & Watt, F. M. Defining adult stem cells by function, not by phenotype. *Annu. Rev. Biochem.* **87**, 1015–1027 (2018).
- Petit, V. et al. Chronic high-fat diet affects intestinal fat absorption and postprandial triglyceride levels in the mouse. *J. Lipid Res.* **48**, 278–287 (2007).
- Beuling, E. et al. GATA factors regulate proliferation, differentiation, and gene expression in small intestine of mature mice. *Gastroenterology* **140**, 1219–1229 (2011).
- Aronson, B. E., Stapleton, K. A. & Krasinski, S. D. Role of GATA factors in development, differentiation, and homeostasis of the small intestinal epithelium. *Am. J. Physiol. Gastrointest. Liver Physiol.* **306**, G474–G490 (2014).

17. Haber, A. L. et al. A single-cell survey of the small intestinal epithelium. *Nature* **551**, 333–339 (2017).
18. Moor, A. E. et al. Spatial reconstruction of single enterocytes uncovers broad zonation along the intestinal villus axis. *Cell* **175**, 1156–1167 (2018).
19. Beumer, J. et al. Enterendocrine cells switch hormone expression along the crypt-to-villus BMP signalling gradient. *Nat. Cell Biol.* **20**, 909–916 (2018).
20. Kraicz, J. et al. DNA methylation defines regional identity of human intestinal epithelial organoids and undergoes dynamic changes during development. *Gut* **68**, 49–61 (2019).
21. Middendorp, S. et al. Adult stem cells in the small intestine are intrinsically programmed with their location-specific function. *Stem Cells* **32**, 1083–1091 (2014).
22. Burtscher, I., Barkey, W. & Lickert, H. Foxa2-venus fusion reporter mouse line allows live-cell analysis of endoderm-derived organ formation. *Genesis* **51**, 596–604 (2013).
23. Wolf, F. A. et al. PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. *Genome Biol.* **20**, 59 (2019).
24. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, N. & Luo, L. A global double-fluorescent cre reporter mouse. *Genesis* **45**, 593–605 (2007).
25. Imuta, Y., Kiyonari, H., Jang, C. W., Behringer, R. R. & Sasaki, H. Generation of knock-in mice that express nuclear enhanced green fluorescent protein and tamoxifen-inducible Cre recombinase in the notochord from Foxa2 and T loci. *Genesis* **51**, 210–218 (2013).
26. Parker, H. E., Gribble, F. M. & Reimann, F. The role of gut endocrine cells in control of metabolism and appetite. *Exp. Physiol.* **99**, 1116–1120 (2014).
27. Clemmensen, C. et al. Gut–brain cross-talk in metabolic control. *Cell* **168**, 758–774 (2017).
28. Gehart, H. et al. Identification of enteroendocrine regulators by real-time single-cell differentiation mapping. *Cell* **176**, 1158–1173 (2019).
29. Buccacki, S. J. A. et al. Intestinal label-retaining cells are secretory precursors expressing *lgr5*. *Nature* **495**, 65–69 (2013).
30. La Manno, G. et al. RNA velocity of single cells. *Nature* **560**, 494–498 (2018).
31. Piccand, J. et al. Rfx6 promotes the differentiation of peptide-secreting enteroendocrine cells while repressing genetic programs controlling serotonin production. *Mol. Metab.* **29**, 24–39 (2019).
32. Martin, A. M. et al. The diverse metabolic roles of peripheral serotonin. *Endocrinology* **158**, 1049–1063 (2017).
33. Barker, N. et al. Identification of stem cells in small intestine and colon by marker gene *Lgr5*. *Nature* **449**, 1003–1007 (2007).
34. Chandel, N. S., Jasper, H., Ho, T. T. & Passequé, E. Metabolic regulation of stem cell function in tissue homeostasis and organismal ageing. *Nat. Cell Biol.* **18**, 823–832 (2016).
35. Ito, K., Bonora, M. & Ito, K. Metabolism as master of hematopoietic stem cell fate. *Int. J. Hematol.* **109**, 18–27 (2019).
36. Dahly, E. M., Guo, Z. & Ney, D. M. Alterations in enterocyte proliferation and apoptosis accompany TPN-induced mucosal hypoplasia and IGF-I-induced hyperplasia in rats. *J. Nutr.* **132**, 2010–2014 (2002).
37. Mah, A. T. et al. Impact of diet-induced obesity on intestinal stem cells: hyperproliferation but impaired intrinsic function that requires insulin/IGF1. *Endocrinology* **155**, 3302–3314 (2014).
38. Mao, J. et al. Overnutrition stimulates intestinal epithelium proliferation through  $\beta$ -catenin signaling in obese mice. *Diabetes* **62**, 3736–3746 (2013).
39. Patel, P. & Woodgett, J. R. Glycogen synthase kinase 3: a kinase for all pathways? *Curr. Top. Dev. Biol.* **123**, 277–302 (2017).
40. Fevr, T., Robine, S., Louvard, D. & Huelsken, J. Wnt/ $\beta$ -catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. *Mol. Cell Biol.* **27**, 7551–7559 (2007).
41. Pinto, D., Gregorieff, A., Begthel, H. & Clevers, H. Canonical Wnt signals are essential for homeostasis of the intestinal epithelium. *Genes Dev.* **17**, 1709–1713 (2003).
42. Aichler, M. et al. N-acyl taurines and acylcarnitines cause an imbalance in insulin synthesis and secretion provoking  $\beta$  cell dysfunction in type 2 diabetes. *Cell Metab.* **25**, 1334–1347 (2017).
43. Shao, W. & Espenshade, P. J. Expanding roles for SREBP in metabolism. *Cell Metab.* **16**, 414–419 (2012).
44. Mihaylova, M. M., Sabatini, D. M. & Yilmaz, Ö. H. Dietary and metabolic control of stem cell function in physiology and cancer. *Cell Stem Cell* **14**, 292–305 (2014).
45. Gao, Y. et al. LKB1 represses ATOH1 via PDK4 and energy metabolism and regulates intestinal stem cell fate. *Gastroenterology* **158**, 1389–1401 (2020).
46. Kinzler, K. W. & Vogelstein, B. Lessons from hereditary colorectal cancer. *Cell* **87**, 159–170 (1996).
47. Nusse, R. & Clevers, H. Wnt/ $\beta$ -Catenin signaling, disease, and emerging therapeutic modalities. *Cell* **169**, 985–999 (2017).
48. Postic, C. & Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. *J. Clin. Investig.* **118**, 829–838 (2008).
49. Ipsen, D. H., Lykkesfeldt, J. & Tveden-Nyborg, P. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. *Cell. Mol. Life Sci.* **75**, 3313–3327 (2018).
50. Kawano, Y. & Cohen, D. E. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. *J. Gastroenterol.* **48**, 434–441 (2013).
51. Namkung, J., Kim, H. & Park, S. Peripheral serotonin: a new player in systemic energy homeostasis. *Molecules Cells* **38**, 1023–1028 (2015).
52. Watanabe, H. et al. Serotonin improves high fat diet induced obesity in mice. *PLoS ONE* **11**, e0147143 (2016).
53. Poher, A. L., Tschöp, M. H. & Müller, T. D. Ghrelin regulation of glucose metabolism. *Peptides* **100**, 236–242 (2018).
54. Tschöp, M. et al. Circulating ghrelin levels are decreased in human obesity. *Diabetes* **50**, 707–709 (2001).
55. Papaetis, G. S. Incretin-based therapies in prediabetes: current evidence and future perspectives. *World J. Diabetes* **5**, 817–834 (2014).
56. Matthews, D. R. et al. Homeostasis model assessment: insulin resistance and  $\beta$ -cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* **28**, 412–419 (1985).
57. Nakajima, S., Hira, T. & Hara, H. Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats. *Br. J. Nutr.* <https://doi.org/10.1017/S0007114515000550> (2015).
58. Chambers, A. P. et al. Weight-independent changes in blood glucose homeostasis after gastric bypass or vertical sleeve gastrectomy in rats. *Gastroenterology* **141**, 950–958 (2011).
59. Panaro, B. L. et al. Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion. *Mol. Metab.* **37**, 100990 (2020).
60. Andersson-Rolf, A., Fink, J., Mustata, R. C. & Koo, B. K. A video protocol of retroviral infection in primary intestinal Organoid culture. *J. Vis. Exp.* <https://doi.org/10.3791/51765> (2014).
61. R Development Core Team, R. Lecture Notes in Physics, R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing <https://doi.org/10.1007/978-3-540-74686-7> (2011).
62. Rainer, J., Sanchez-Cabo, F., Stocker, G., Sturm, A. & Trajanoski, Z. CARMAweb: Comprehensive R- and bioconductor-based web service for microarray data analysis. *Nucleic Acids Res.* **34**, W498–W503 (2006).
63. Mantini, D. et al. LIMPIC: a computational method for the separation of protein MALDI-TOF-MS signals from noise. *BMC Bioinforma.* **8**, 101 (2007).

## Acknowledgements

We thank J. Schultheiss, K. Diemer, I. Kunze, S. Felicitas Baumgarten, A. Raducanu, A. Theis, A. Bettenbrock and S. Straub for excellent technical assistance. We thank B. Schubert and E. Spiegel for their input and help for the compositional analysis and M. Büttner, A. Wolf, L. Simon and D. Fischer for fruitful discussions on the computational analysis. We are grateful to H. Edlund for providing the Ngn3 antibody. We thank M. Bakhti and R. Böttcher for valuable comments on the manuscript. This work was funded by the Helmholtz Alliance ICeMED: Imaging and Curing Environmental Metabolic Diseases (H.L., K.S. and M.H.T.), through the Initiative and Networking Fund of the Helmholtz Association (H.L.) and the Deutsche Forschungsgemeinschaft (SFB 824 C4 and CRC/Transregio 205/1) (A.W.). For financial support we also thank the Helmholtz Society, the Helmholtz Portfolio Theme ‘Metabolic Dysfunction and Common Disease’ (H.L., K.S. and M.H.T.), the Helmholtz Alliance ‘Aging and Metabolic Programming, AMPro’ (H.L. and J.B.). Further, this project was funded by ExNet-0041-Phase2–3 (‘SyNergy-HMGU’) through the Initiative and 354Network Fund of the Helmholtz Association (H.L. and F.J.T.), the German Research Foundation and the German Center for Diabetes Research (H.L., K.S. and M.H.T.), the Alexander von Humboldt Foundation (M.H.T.), Helmholtz Initiative on Personalized Medicine iMed by Helmholtz Association (M.H.T.), the Deutsche Forschungsgemeinschaft (DFG; German Research Foundation Grants DFG-TS226/1-1, DFG-TS226/3-1 and DFG-TR152 (project no. 239283807) (M.H.T.) and DFG-SFB 1321 (K.S. and M.H.T.) and the European Research Council (AdG HypoFlam 695054) (M.H.T.). S.T. is supported by a DFG Fellowship through the Graduate School of Quantitative Biosciences Munich.

## Author contributions

A.A. performed all rodent experiments, intestinal histology and western blots, and analysed and interpreted all data, interpreted scRNA-seq data and co-wrote the manuscript. S.T. analysed and interpreted scRNA-seq data and co-wrote the manuscript. M.S. analysed microarray data. L.O. analysed data and performed in vivo experiments. J.H. performed intestinal histology and analysed histology data. T.G. performed RNAscope staining. M.I. and J.B. performed microarray analysis. N.S. and A.W. performed MALDI-MSI and analysed data. K.S. helped with metabolic profiling in mice. M.H.T. helped to interpret data. A.K. and J.K. integrated and analysed microarray data and metabolomics data. M.D.L. supported scRNA-seq analysis. F.J.T. conceptualized, supervised and interpreted the scRNA-seq analysis and helped to write the manuscript. H.L. acquired funding and conceptualized, designed, supervised and interpreted all studies, co-wrote the manuscript and is the lead contact for this work. A.B. conceptualized, designed, supervised and interpreted all studies, performed experiments and co-wrote the manuscript.

### Funding

Open access funding provided by Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH).

### Competing interests

M.H.T. serves as a scientific advisory board member of ERX Pharmaceuticals, Inc, Cambridge, MA. F.J.T. reports receiving consulting fees from Cellarity, Inc and ownership interest in Cellarity, Inc. and Dermagnostix. S.T. is an employee of Cellarity, Inc. and has stake-holder interests; the present work was carried out as an employee of Helmholtz Munich. The remaining authors declare no competing interests.

### Additional information

**Extended data** is available for this paper at <https://doi.org/10.1038/s42255-021-00458-9>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s42255-021-00458-9>.

**Correspondence and requests for materials** should be addressed to Fabian J. Theis, Heiko Lickert or Anika Böttcher.

**Peer review information** Primary handling editors: Elena Bellafante and Isabella Samuelson. *Nature Metabolism* thanks Shalev Itzkovitz and the other, anonymous, reviewers for their contribution to the peer review of this work.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).


**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.


© The Author(s) 2021





Extended Data Fig. 1 | See next page for caption.

**Extended Data Fig. 1 | HFHSD remodels the intestinal mucosa and leads to obesity and prediabetes.** **a**, Weekly assessment of body weight.  $n = 8$  mice per group. Data are shown as mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-way ANOVA with Sidak's multiple comparison test. **b–d**, Analysis of fat (**b**) and lean mass (**c**) by nuclear magnetic resonance (NMR) and fat mass ratio (**d**).  $n = 3$  mice per group. Data are shown as mean  $\pm$  s.e.m.. Statistical significance was determined by two-tailed Student's *t*-test. **e, f**, Assessment of small intestinal length (**e**,  $n = 10$  mice per group) and weight (**f**,  $n = 8$  mice versus 10 mice per group). Data are shown as mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test. **g–m**, Representative LSM images of duodenal sections depicting crypt-villus units (**g**) or crypt regions (**k**). Assessment of crypt and villus morphology in duodenal and ileal sections. Duodenum: **h, j, l, m**. Ileum: **i**,  $n = 8$  mice versus 7 mice (**h**),  $n = 3$  mice (**i, j**),  $n = 4$  mice (**l**) and  $n = 8$  mice (**m**) per group. Data are shown as mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test. Scale bars, 75  $\mu\text{m}$  (**g**), 25  $\mu\text{m}$  (**k**). **n–p**, Cell number (**n**) and size (**o**) quantification in the crypts ( $n = 4$  mice per group) and cell size quantification in the villi (**p**,  $n = 3$  mice per group). Data are mean  $\pm$  s.e.m. of biologically independent samples. **q**, Histological assessment of duodenal tissue sections by haematoxylin and eosin staining. Black square depicts an enlarged villus section. Black arrowheads indicate fat inclusions. Scale bar, 100  $\mu\text{m}$ .  $n = 3$  biologically independent CD and HFHSD samples. **r, s**, Assessment of glucose tolerance (**r**,  $n = 8$  per group) by oral glucose tolerance test (oGTT) and insulin secretion (**s**,  $n = 4$  mice versus 5 mice per group) by insulin secretion test (IST). Data are shown as mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-way ANOVA with Sidak's multiple comparison test. **t, u**, Estimation of insulin resistance ((HOMA-IR) and  $\beta$ -cell function (HOMA- $\beta$ ).  $n = 6$  mice per group. Data are shown as mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test.




Extended Data Fig. 2 | See next page for caption.


**Extended Data Fig. 2 | Characterization of small intestinal epithelial cell types and lineage relations in CD- and HFHSD-conditions by scRNA-seq.**

**a**, Representative flow cytometry plot for FVF-based enrichment of SI crypt cells for scRNA-seq. Gating strategy distinguishes FVF-positive cells from random live whole crypt cells (FVF all). **b**, Quality metrics for the scRNA-seq data. **c**, Levels of cell scores calculated based on the expression of a set of known marker genes specific for each cell type and used for cluster annotation. Violin plots show distribution of score levels assigned to the respective cell type in CD- and HFHSD-derived samples. **d**, UMAP plots of crypt cells colored by cell densities of individual CD and HFHSD mice. **e**, Mean expression levels of selected genes known to regulate lineage decisions in intestinal crypt cells of CD and HFHSD mice. \*indicates a significant change in HFHSD mice (limma, FDR < 0.01, logFC > 0.1). **f**, Lineage relations in CD- and HFHSD-derived SI crypt cells inferred based on a measure for cluster connectivity using PAGA. Edges are weighted by significance, node positions are cluster centres in UMAP space. **g**, Pearson correlation of mean expression profiles of high variance genes broken down by cell type and diet. Rows and columns are ordered using hierarchical clustering. **h**, Frequency shifts of each cluster from HFHSD-derived samples compared to CD-derived samples estimated using a Dirichlet-Multinomial model. Expected mean and the 95% highest posterior density interval (HPD-region) of the frequency shift for each cell type is shown. A credible shift is assumed if the HPD-region does not include 0.  $n = 3$  CD mice.  $n = 3$  HFHSD mice.






**Extended Data Fig. 3 | Proximal- and distal-type enterocytes exert different functions. a,** Violin plots showing expression distribution of regional markers *Oneucut2* (proximal) and *Bex1* (distal) used to classify proximal and distal cells<sup>17</sup> (see Methods). **b,** Genes and their associated function characteristic for enterocytes with proximal or distal identity, respectively. Heatmap shows estimated fold change in proximal versus distal cells from CD-derived samples.




**Extended Data Fig. 4 | Analysis of *Foxa2* lineage positive cells and frequency of mature intestinal cell types in FVF mice in CD and HFHSD conditions.**

**a**, Representative LSM images of tamoxifen-induced recombination in duodenal crypts of CD- and HFHSD-fed *Foxa2*<sup>nEGFP-CreERT2/+</sup>; *Gt(Rosa26)*<sup>mTmG/+</sup> mice after 48 h. Yellow arrows indicate recombined mG<sup>+</sup> slender crypt base cells (CBC) at positions typical for ISCs, adjacent to pyramid-shaped Paneth cells. Scale bar, 25  $\mu$ m. *n* = 3 biologically independent CD and HFHSD samples. **b**, Frequencies of coherent *Foxa2*-lineage ribbons of different sizes in the villi of CD- and HFHSD-fed *Foxa2*<sup>nEGFP-CreERT2/+</sup>; *Gt(Rosa26)*<sup>mTmG/+</sup> mice at 70 h after tamoxifen induction. *n* = 3 mice per group. Data are mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test. **c**, Percentage of villin<sup>+</sup> enterocytes, Muc2<sup>+</sup> goblet cells and ChgA<sup>+</sup> EECs within *Foxa2* lineage ribbons. *n* = 3 mice per group. Data are mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test. **d**, **e**, Quantification of ChgA<sup>+</sup> EECs (**d**, *n* = 3 mice per group) and Muc2<sup>+</sup> goblet cells (**e**, *n* = 4 mice per group) in ileal tissue sections of CD- and HFHSD-fed FVF mice. Data are shown as mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test. **f**, **g**, Representative LSM images (**f**) and quantification (**g**) of Paneth cells (Lyz1<sup>+</sup>) in the duodenum. Scale bar, 25  $\mu$ m, *n* = 8 mice per group. Data are mean  $\pm$  s.e.m. of biologically independent samples.



**Extended Data Fig. 5 | Regional identity of villi enterocytes is changed upon HFHSD.** **a**, Overview of the experimental setup for scRNA-seq of villi cells. **b**, UMAP plot of 4205 profiled single SI villi cells. Colors highlight clustering into major intestinal cell types based on expression of previously published marker genes<sup>17</sup>. **c**, UMAP plot of enterocyte progenitors (EP) and enterocytes computed using a set of 44 transcription factors previously described to be differential between proximal and distal gut regions<sup>17</sup>. Colors highlight diet. **d**, UMAP plot of EP and enterocytes computed using a set of 44 transcription factors previously described to be differential between proximal and distal gut regions<sup>17</sup>. Colors highlight regional annotation. **e**, Violin plots showing cell scores of the proximal and distal transcription factors used in c)<sup>17</sup> in CD and HFHSD-derived EPs and enterocytes. **f**, Proportions of enterocytes and EPs annotated as proximal- or distal-type enterocytes based on regional transcription factor scores in c). **g**, Heatmap showing the log2- fold change of the expression of selected functional proximal genes in HFHSD vs CD distal and proximal enterocyte cluster. \*indicates a significant change. The p-values are provided in Supplementary table 1.




Extended Data Fig. 6 | See next page for caption.



**Extended Data Fig. 6 | Enterocyte zonation is altered upon HFHSD.** **a**, Activation of zonation scores along a pseudospacial ordering of EP and enterocytes from SI villi, which reflects the axis from villus bottom to tip. Cell scores for each zone were computed on reported markers<sup>18</sup> and approximated by polynomial regression fits along the pseudospacial axis. Crossing points of the fitted lines define the partitioning into the five zones. **b**, Dot plots showing the expression of selected markers of enterocyte function in distal and proximal enterocytes. Cells are partitioned into zones along the inferred pseudospacial axis from villus bottom (zone 1) to tip (zone 5). **c–e**, Representative LSM images (**c**) and quantification of Fabp1 mean fluorescence intensity in ileal villi (**d**) and determination of the length of the Fabp1 positive zone (**e**). Scale bar, 50  $\mu\text{m}$ ,  $n=3$  CD mice and  $n=4$  HFHSD mice. Data are shown as mean  $\pm$  s.d. of biologically independent samples. Statistical significance was determined by two-tailed Student's t-test. **f–h**, Representative LSM images (**f**) and quantification of Apoa4 mean fluorescence intensity in ileal villi (**g**) and determination of the length of the Apoa4 positive zone (**h**). Scale bar, 50  $\mu\text{m}$ ,  $n=3$  CD mice and  $n=4$  HFHSD mice. Data are shown as mean  $\pm$  s.d. of biologically independent samples. Statistical significance was determined by two-tailed Student's t-test. **i–k**, Representative LSM images (**i**) and quantification of Apoa4 mean fluorescence intensity in duodenal villi (**j**) and determination of the length of the Apoa4 positive zone (**k**). Scale bar, 50  $\mu\text{m}$ ,  $n=5$  mice per group. Data are shown as mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's t-test.




**Extended Data Fig. 7 | HFHSD changes transcription in EEC subsets and gut plasma hormone levels.** **a**, Violin plots showing the distribution of expression of selected genes in EEC clusters. **b**, PAGA plot showing lineage relationships for the endocrine lineage in CD-derived samples. **c**, Mean expression levels per cluster of genes associated with BMP signaling. **d**, Mean expression levels per cluster of subset-specific genes in EEC clusters. **e**, Frequency shifts of each cluster from HFHSD-derived samples compared to CD-derived samples estimated using a Dirichlet-Multinomial model. Expected mean and the 95% highest posterior density interval (HPD-region) of the frequency shift for each cell type is shown.  $n = 3$  mice per group. **f–i**, Abundance of label-retaining cells (LRCs). **f**, Schematic depicting the experimental strategy of the 5-bromo-2-deoxyuridine (BrdU) pulse-chase experiment to determine the LRC frequency. **g**, Representative LSM images of duodenal sections after 14 days of BrdU labelling. BrdU-labelled cells are stained in red. Scale bar,  $50\ \mu\text{m}$ .  $n = 3$  biologically independent CD and HFHSD mice. **h**, Representative LSM images of duodenal crypts after a chase period of 21 days. Yellow arrowhead highlights a  $\text{BrdU}^+/\text{Lyz1}^-$  LRC. Blue arrowheads indicate  $\text{BrdU}^+/\text{Lyz1}^+$  cells. Scale bar,  $25\ \mu\text{m}$ . **i**, Proportion of  $\text{Lyz1}^-$  and  $\text{Lyz1}^+$  BrdU-labelled cells of total  $\text{BrdU}^+$  cells in duodenal crypts.  $n = 4$  mice versus 5 mice per group. Data are presented as mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's *t*-test. **j**, Mean hormone expression levels in EECs. Mean was calculated only from cells with high expression levels ( $\log(\text{count}) > 3$ ). **k–m**, Differential gene expression in selected EEC clusters tested using limma. For each gene, the estimated logFC and its associated FDR is plotted. Red lines indicate thresholds used for significance level and gene expression change. Regulated genes are highlighted in black, of which annotated genes are the top 10 genes ranked by FDR. **n**, Experimental scheme for the assessment of selected hormone plasma levels. **o–q**, Plasma levels of serotonin ( $n = 4$  mice per group) (**o**), ghrelin ( $n = 5$  mice / 4 mice per group) (**p**) and Glp-1 ( $n = 5$  mice / 4 mice per group) (**q**). Data represent mean  $\pm$  s.e.m. of biologically independent mice. Statistical significance was determined by two-tailed Student's *t*-test.




Extended Data Fig. 8 | See next page for caption.



**Extended Data Fig. 8 | HFHSD increases turnover of SI crypt cells.** **a**, Left: Cell score levels for cell-cycle phases S and G2/M calculated based on the expression of a set of genes related to cell-cycle are visualized in a UMAP plot. Right: Cells assigned to the corresponding cell-cycle phase are highlighted in red. **b**, Proportions of cycling cells assigned to S and G2/M cell-cycle phases in CD and HFHSD-derived in indicated clusters. Table indicates percentages. Data are shown as mean  $\pm$  s.e.m.,  $n=3$  mice per group. **c**, Assessment of body weight over the course of 14 weeks of CD- and HFHSD-fed Lgr5-ki mice.  $n=4$  per group. Data are shown as mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's t-test. **d**, Representative FACS plots showing gating strategy to determine the proportion of Lgr5-EGFP<sup>hi</sup> cells (ISCs) in CD and HFHSD fed Lgr5-ki mice. **e, f**, Representative LSM images (**e**) and quantification (**f**) of Ki67<sup>+</sup> (green) proliferative regions. Scale bar, 75  $\mu$ m,  $n=4$  mice per group. Data are mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's t-test. **g-i**, Representative LSM images of BrdU-labelled cells (BrdU<sup>+</sup> nuclei, red) along the crypt-villus axis 24 h after BrdU administration in duodenal sections from CD- and HFHSD-fed FVF mice (**g**). Quantification of cell migration length by measuring the distance from the crypt base to the highest labelled cell in the villus (**h**). Net BrdU migration (**i**), calculated as the average distance of BrdU-labelled migration front minus the Ki67<sup>+</sup> zone to correct for increased cell proliferation on HFHSD. Scale bar, 25  $\mu$ m.  $n=4$  mice per group. Data are mean  $\pm$  s.e.m. of biologically independent samples. Statistical significance was determined by two-tailed Student's t-test.



**Extended Data Fig. 9 | HFHSD stimulates the Insr/Igf1r/Akt pathway and fatty acid synthesis and Ppar signaling.** **a, b**, Representative immunoblots of phosphorylated (p)Igf1r/Insr (Tyr1158/Tyr1162/Tyr1163) and total Igf1r, Insrβ, pAkt (Ser473) and total Akt (**a**) and quantification of the protein levels (**b**). Protein expression was analysed in whole-cell lysates from SI crypts of CD- and HFHSD-fed FVF animals. For quantification, signal intensities of all protein bands were normalised to α-tubulin; phosphorylated proteins were additionally normalised to the corresponding non-phosphorylated protein.  $n = 3$  mice per group for pIgf1r/pInsr,  $n = 7$  mice per group for Igf1r,  $n = 9$  mice per group for (p)Akt and total Akt. Data are presented as box-and-whisker plots. The lower and upper boundaries of the boxes represent the 25th and 75th percentiles, respectively. The center lines indicate the medians, the crosses denote the mean values, and whiskers represent the maximum and minimum values. Statistical significance was determined by two-tailed Student's *t*-test. Circles represent biological independent samples. **c**, Mean expression levels per cluster of genes involved in PI3K/Akt signaling in CD and HFHSD. \* indicates a significant change in HFHSD mice (limma, FDR < 0.01, logFC > 0.1). The *p*-values are provided in Supplementary table 1. **d**, Predicted activation or inhibition of upstream regulators in bulk transcriptomics. Significantly regulated genes from each population (each HFHSD versus CD) were analysed by Ingenuity Pathway Software to predict the activation (yellow;  $z$ -score > 2) or inhibition (blue;  $z$ -score < -2) of upstream regulators. Shown are all genes with three *z*-scores available and from which at least two were significant ( $z$ -score > 12 I).



**Extended Data Fig. 10 | Confirmation of expression differences in metabolic genes in FVF-positive cells from CD- and HFHSD-fed mice by targeted single-cell qPCR. a, b**, UMAP plot of 465 profiled FVF positive crypt cells from 3 CD and 3 HFHSD-fed mice coloured by cell type (**a**). Cluster annotation was based on lineage marker gene expression depicted in the heatmap (**b**). **c**, Violin plots showing expression of selected metabolic genes related to fatty acid synthesis, Ppar signaling and glycolysis in indicated single-cell clusters split by diet.

## Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- ☐ ☒ The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- ☐ ☒ A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- ☐ ☒ The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- ☐ ☒ A description of all covariates tested
- ☐ ☒ A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- ☐ ☒ A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- ☐ ☒ For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- ☒ ☐ For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- ☒ ☐ For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- ☐ ☒ Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

### Software and code

Policy information about [availability of computer code](#)

#### Data collection

1. Microsoft office excel 2016-2018
2. qPCR was carried out using the Viia7 Real Time PCR System (Thermo Fisher Scientific).
3. Microarray data was obtained using Agilent 2100 Bioanalyzer and Affymetrix Mouse Gene 1.0 ST arrays.
4. MALDI-MSI measurements were obtained with a Bruker Solarix 7T FT-ICR-MS (Bruker Daltonics, Bremen, Germany) and after matrix removal scanned with a MIRAX DESK digital slide-scanning system (Carl Zeiss MicroImaging, Göttingen, Germany).
5. Western blot analysis was carried out using UVP Chem Studio SA (Analytik Jena AG, Biometra GmbH Jena Germany).
6. Tissue histology images were obtained with a Zeiss AXIO Scope A1 microscope (Carl Zeiss AG, Germany).
7. Fluorescent histological images were obtained with a Leica SP5 Confocal microscope (Leica Microsystems, Germany) using the LAS AF software v2.6.0-7266.
8. single-cell qRT-PCR were run on 96 × 96 Dynamic Array on the BioMark System (Fluidigm). Ct values for each gene in each cell was calculated using BioMark Real-Time PCR Analysis software v3 (Fluidigm).
9. single-cell libraries were sequenced on the HiSeq4000 (Illumina) with 150 bp paired-end sequencing of read 2.
10. BD FACS ARIA III and BD FACSDiva software v6.1.3
11. EchoMRI, Houston, TX, USA for body composition analysis

#### Data analysis

1. Prism 6 software (Graphpad) <http://www.graphpad.com/scientific-software/> N/A prism/.
2. Microarray was processed with Expression Console (v.1.3.0.187, Affymetrix),
3. Spectra processing of MALDI-MSI data was done with FlexImaging v. 4.2.
4. MATLAB R2014b (v.7.10.0, Mathworks, Inc., Natick, MA) was used as MALDI spectral pre-processing tool for the subsequent data bioinformatics analysis, LIMPIC algorithm was used for peak picking
5. Metabolite annotation was performed with databases (METLIN, <http://metlin.scripps.edu/>; Human Metabolome Database, <http://www.hmdb.ca/>; MassTRIX, <http://masstrix3.helmholtz-muenchen.de/masstrix3/>; METASPACE, <http://annotate.metaspacesoftware.com/>).
6. Heatmap-based clustering and enrichment analysis of metabolic pathways were performed with MetaboAnalyst 3.0 (<http://www.metaboanalyst.ca/>).
7. Western blots protein bands were quantified with the ImageJ software v1.51.



8. Histological images were analyzed using the LAS AF software program v2.6.0-7266..
9. scRNA-seq data were analyzed using python 3.5.4, 3.6.12 and 3.7.5. The raw reads were processed using the CellRanger analysis pipeline (v2.0.0) provided by 10X Genomics. Subsequent analyzes were carried out using custom scripts, Scanpy (<https://github.com/theislab/scanpy>, v1.0.4+92.g9a754bb and 1.4.4post for velocity estimation and scRNA-seq of villi cells), scVelo (0.1.26.dev7+g5e6d395, <https://github.com/theislab/scvelo> with scanpy v1.3.4), velocity (v0.17.7, <http://velocityto.org>), limma (<http://bioinf.wehi.edu.au/limma/>, v3.28.10) via an rpy2 interface (v2.9.1) and gseapy (v0.9.3) implementation of EnrichR (2018/2019).
10. QIAGEN's Ingenuity Pathway Analysis (IPA®, QIAGEN Redwood City, [www.qiagen.com/ingenuity](http://www.qiagen.com/ingenuity)).
11. CARMAweb

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

## Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

All data generated or analysed during this study are included in this published article and its Supplementary Information files. Source data are provided with this paper.

Microarray data have been submitted to NCBI/GEO (GSE148227).

scRNAseq data have been submitted to NCBI/GEO (GSE147319).

Code and custom scripts for scRNAseq analysis have been deposited on [https://github.com/theislab/2021\\_Aliluev\\_Tritschler\\_gut\\_HFD](https://github.com/theislab/2021_Aliluev_Tritschler_gut_HFD).

Databases: <http://metlin.scripps.edu/>; Human Metabolome Database, <http://www.hmdb.ca/>; MassTRIX, <http://masstrix3.helmholtz-muenchen.de/masstrix3/>;

METASPACE, <http://annotate.metaspace2020.eu/>

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](http://nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	<p>Sample size was calculated based on <math>\alpha</math>-error=0.05, power=0.8, and effect size=1.58. We obtained a sample size of <math>n \geq 8</math>/condition group for physiological measurements during the high-fat high sugar diet feeding based on published data.</p> <p>For single-cell RNA-seq a minimum expected requirement of ~3000 cells per experiment was used and by far exceeded in all cases for confident identification of rare cell subpopulations (~0.05% of cells). No statistical test or power analyzes were used to pre-determine sample size.</p> <p>Otherwise, we chose the sample size of individual experiments based on past experience on detecting differences with a given method and relevant literature (PMID: 26935695, PMID: 22722868, PMID: 29727683).</p>
Data exclusions	<p>For the single-cell RNAseq data cells were filtered using previously described standards for quality control. For each experiment the count matrix was filtered as follows: for scRNA-seq samples of crypt cells genes with expression in less than 20 cells were removed and cells with a fraction of UMI counts from mitochondrially encoded genes of 10% or more were excluded, for scRNA-seq samples of villi cells genes with expression in less than 5 cells were removed and cells with a fraction of UMI counts from mitochondrially encoded genes of 25% or more were excluded. These criteria were based on the cell quality within this study. Otherwise, no data were excluded. Some mice that were on a HFHSD did not gain weight (=non-responder) and were excluded from the analysis.</p>
Replication	<p>Experiments were performed at least in triplicates most with three or more biological replicates unless otherwise indicated. All attempts of replication were successful. Further details about the replication of data are stated in the figure legends.</p>
Randomization	<p>For dietary interventions mice were randomized into test groups based on body weight distribution. For microscopy, the fields of images were randomly selected. For FACS experiments, at least 50,000 events were randomly sampled by the FACS machine. Most other results were derived from computation therefore randomization was not required.</p>
Blinding	<p>The investigators were not blinded to group allocation during in vivo experiments as CD and HFHSD mice were clearly distinguishable by eye. Investigators were not blinded during data collection or analysis as most experiments/analyses were performed by automatic devices such as the FACS or qPCR cyclers. For cell-based assays such as Western blot or qPCR blinding was not possible because the experiments were performed by a single researcher.</p>

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

## Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology
<input type="checkbox"/>	<input checked="" type="checkbox"/> Animals and other organisms
<input checked="" type="checkbox"/>	<input type="checkbox"/> Human research participants
<input checked="" type="checkbox"/>	<input type="checkbox"/> Clinical data

## Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input type="checkbox"/>	<input checked="" type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

### Antibodies used

primary antibodies:  
 chicken anti-GFP (1:600, Aves Labs, USA, GFP-1020);  
 goat anti-ChgA (1:200, Santa Cruz, sc-1488);  
 rabbit anti-Lyz1 (1:1000, DAKO, M0776);  
 rabbit anti-Muc2 (1:1000, Santa Cruz, sc-7314);  
 rat anti-BrdU (1:200, Abcam, ab6326);  
 rabbit anti-5-HT (1:1000, Neuromics, RA20080);  
 anti-rabbit Ngn3 (1:100, a gift from Helena Edlund lab);  
 goat anti-villin (1:200, Santa Cruz, sc-7672);  
 goat anti-ghrelin (1:200, Santa Cruz, sc-10368);  
 rabbit anti-Ki67 (1:200, Abcam, ab15580);  
 rabbit anti-E-cadherin (extracellular domain) (1:1000, a gift from Dietmar Vestweber)  
 mouse anti-Srebp1 (1:1000, Novus Biologicals, NB600-582SS);  
 rabbit anti-Acc (1:1000, Cell Signaling Technology, 3676);  
 rabbit anti-Ppary (1:1000, Cell Signaling Technology, 2435);  
 goat anti-lamin (1:1000, Santa Cruz, sc-6217);  
 mouse anti- $\alpha$ -tubulin (1:1000, Sigma-Aldrich, T6199);  
 rabbit anti-Fasn 1:1000, Cell Signaling Technology, 3180);  
 rabbit anti-Scd1 (1:1000, Cell Signaling Technology, 2794);  
 mouse anti- $\beta$ -Catenin (1:1000, BD, 610154);  
 rabbit anti-Gsk3 $\beta$  (1:5000, Cell Signaling Technology, 12456);  
 rabbit anti-phospho Gsk3 $\beta$  (1:5000, Cell Signaling Technology, 5558)

Secondary antibodies:  
 donkey anti-chicken Alexa Fluor 488 (1:800, Dianova, 703-225-155);  
 donkey anti-mouse Cy5 (1:800, Dianova, 715-175-151);  
 donkey anti-goat Alexa Fluor 555 (1:800, Invitrogen, A21432);  
 donkey anti-rabbit Alexa Fluor 555 (1:800, Invitrogen, A31572);  
 donkey anti-rabbit Alexa Fluor 649 (1:800, Dianova, 711-605-152);  
 goat anti-mouse HRP (1:15000, Dianova, 115-036-062);  
 goat anti-rabbit HRP (1:15000, Dianova, 111-036-045);  
 rabbit anti-goat HRP (1:15000, Dianova, 305-035-045)

### Validation

primary antibodies: antibodies were validated by the company  
 chicken anti-GFP (1:600, Aves Labs, USA, GFP-1020); <https://www.aveslabs.com/products/green-fluorescent-protein-gfp-antibody>  
 goat anti-ChgA (1:200, Santa Cruz, sc-1488); <https://www.scbt.com/de/p/chr-a-antibody-c-20>  
 rabbit anti-Lyz1 (1:1000, DAKO, M0776); <https://www.labome.com/product/Dako/A0099.html>  
 rabbit anti-Muc2 (1:1000, Santa Cruz, sc-7314); <https://www.scbt.com/p/mucin-2-antibody-ccp58>  
 rat anti-BrdU (1:200, Abcam, ab6326); <https://www.abcam.com/brdu-antibody-bu175-icr1-proliferation-marker-ab6326.html>  
 rabbit anti-5-HT (1:1000, Neuromics, RA20080); <https://www.neuromics.com/RA20080>  
 anti-rabbit Ngn3 (1:100, a gift from Helena Edlund lab); as a control we used a secondary antibody only control, <https://pubmed.ncbi.nlm.nih.gov/31160421/>  
 goat anti-villin (1:200, Santa Cruz, sc-7672); <https://www.scbt.com/de/p/villin-antibody-c-19>  
 goat anti-ghrelin (1:200, Santa Cruz, sc-10368); <https://www.scbt.com/p/ghrelin-antibody-c-18>  
 rabbit anti-Ki67 (1:200, Abcam, ab15580); <https://www.abcam.com/ki67-antibody-ab15580.html>  
 rabbit anti-E-cadherin (extracellular domain) (1:1000, a gift from Dietmar Vestweber)  
 mouse anti-Srebp1 (1:1000, Novus Biologicals, NB600-582SS); [https://www.novusbio.com/products/srebp1-antibody-2a4\\_nb600-582](https://www.novusbio.com/products/srebp1-antibody-2a4_nb600-582)  
 rabbit anti-Acc (1:1000, Cell Signaling Technology, 3676); <https://www.cellsignal.de/products/primary-antibodies/acetyl-coa-carboxylase-c83b10-rabbit-mab/3676>

rabbit anti-Ppary (1:1000, Cell Signaling Technology, 2435); <https://www.cellsignal.de/products/primary-antibodies/pparg-c26h12-rabbit-mab/2435>  
 goat anti-lamin (Santa Cruz, sc-6217); <https://www.scbt.com/de/p/lamin-b-antibody-m-20>  
 mouse anti- $\alpha$ -tubulin (Sigma-Aldrich, T6199); <https://www.sigmaaldrich.com/catalog/product/sigma/t6199?lang=de&region=DE>  
 rabbit anti-Fasn 1:1000, Cell Signaling Technology, 3180); <https://www.cellsignal.de/products/primary-antibodies/fatty-acid-synthase-c20g5-rabbit-mab/3180>  
 rabbit anti-Scd1 (1:1000, Cell Signaling Technology, 2794); <https://www.cellsignal.de/products/primary-antibodies/scd1-c12h5-rabbit-mab/2794>  
 mouse anti- $\beta$ -Catenin (BD, 610154); <https://www.bdbiosciences.com/us/applications/research/stem-cell-research/cancer-research/human/purified-mouse-anti--catenin-14beta-catenin/p/610154>  
 rabbit anti-Gsk3 $\beta$  (1:5000, Cell Signaling Technology, 12456); <https://www.cellsignal.de/products/primary-antibodies/gsk-3b-d5c5z-xp-rabbit-mab/12456>  
 rabbit anti-phospho Gsk3 $\beta$  (1:5000, Cell Signaling Technology, 5558); <https://www.cellsignal.de/products/primary-antibodies/phospho-gsk-3b-ser9-d85e12-xp-rabbit-mab/5558>

#### Secondary antibodies:

donkey anti-chicken Alexa Fluor 488 (Dianova, 703-225-155); <https://www.dianova.com/en/shop/703-175-155-donkey-igg-anti-chicken-igy-hl-cy5-minx-bogogphshohumsrbrtsh/>  
 donkey anti-mouse Cy5 (Dianova, 715-175-151); <https://www.dianova.com/en/shop/715-175-151-donkey-igg-anti-mouse-igg-hl-cy5-minx-bogogphshohurbtrsh/>  
 donkey anti-goat Alexa Fluor 555 (Invitrogen, A21432); <https://www.thermofisher.com/antibody/product/Donkey-anti-Goat-IgG-H-L-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-21432>  
 donkey anti-rabbit Alexa Fluor 555 (Invitrogen, A31572); <https://www.thermofisher.com/antibody/product/Donkey-anti-Rabbit-IgG-H-L-Highly-Cross-Adsorbed-Secondary-Antibody-Polyclonal/A-31572>  
 donkey anti-rabbit Alexa Fluor 649 (Dianova, 711-605-152); <https://www.dianova.com/shop/711-605-152-esel-igg-anti-kaninchen-igg-hl-alex-fluor-647-minx-bogogphshohumsrtrsh/>  
 goat anti-mouse HRP (1:15000, Dianova, 115-036-062); <https://www.dianova.com/shop/115-036-062-ziege-fab2-anti-maus-igg-hl-hrpo-minx-huboho/>  
 goat anti-rabbit HRP (1:15000, Dianova, 111-036-045); <https://www.dianova.com/shop/111-036-045-ziege-fab2-anti-kaninchen-igg-hl-hrpo-minx-hu/>  
 rabbit anti-goat HRP (1:15000, Dianova, 305-035-045); <https://www.dianova.com/shop/305-035-045-kaninchen-igg-anti-ziege-igg-hl-hrpo-minx-hu/>

## Animals and other organisms

Policy information about [studies involving animals](#); [ARRIVE guidelines](#) recommended for reporting animal research

### Laboratory animals

Homozygous Foxa2-Venus fusion (FVF) mice were generated as previously described and backcrossed to C57BL/6 background. Foxa2nEGFP-CreERT2 mice (CD1 background) were crossed with Gt(ROSA)26mTmG mice (mixed 129/SvJ, C57BL/6J background) to obtain heterozygous Foxa2nEGFP-CreERT2/+; Gt(ROSA)26 mTmG/+ animals and bred in our own facilities. Other mouse lines: Lgr5-EGFP-IRES-creERT232 (Lgr5-ki, C57BL/6J background), wild-type C57BL/6N (bred in our own facilities). Mice were housed in groups of two to four animals and maintained at 23  $\pm$  1 °C on a 12-hour dark/light cycle with ad libitum access to diet and water unless otherwise indicated. All experiments were performed using male animals 3 to 7 months of age.

All experiments were performed using 3-7-month-old male mice. Mice were housed in groups of two to four animals and maintained at 23  $\pm$  1 °C and 45-65 % humidity on a 12-hour dark/light cycle with ad libitum access to diet and water unless otherwise indicated.

### Wild animals

The study did not involve wild animals

### Field-collected samples

No field collected samples were used in this study.

### Ethics oversight

Animal experiments were carried out in compliance with the German Animal Protection Act and with the approved guidelines of the Society of Laboratory Animals (GV-SOLAS) and of the Federation of Laboratory Animal Science Associations (FELASA). This study was approved by the institutional Animal Welfare Officer (Helmholtz Center Munich) and by the Government of Upper Bavaria, Germany.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Flow Cytometry

### Plots

Confirm that:

- ☒ The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- ☒ The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- ☒ All plots are contour plots with outliers or pseudocolor plots.
- ☒ A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	<p>Small intestines were removed and washed with cold PBS. Villi were scraped off with a glass slide. The remaining tissue was cut into 2-cm pieces, washed several times with cold PBS and incubated in 2 mM EDTA/PBS for 35 min at 4 °C on a tube roller. Subsequently, crypts were harvested by rigorous shaking and filtered through a 70-µm mesh to remove villous contaminations/ fragments.</p> <p>Isolated crypts were incubated with TrypLE (Life technologies, #12605) for 5 min on ice and then 5 min at 37 °C and treated with 10 µg/ml DNase in crypt complete medium (DMEM/F-12 containing 10 % FCS) for 5 min at 37 °C.</p> <p>Single cell suspension was achieved by gentle repeated pipetting. Cells were washed twice with FACS buffer (2 % FCS, 2 mM EDTA in PBS) and pelleted at 300xg, 5 min, 4 °C. For flow cytometry, cells were collected in 1-2 ml FACS buffer supplemented with 10 µM Rock-inhibitor (Sigma-Aldrich, #Y0503) and passed through the 40 µm cell strainer caps of FACS tubes.</p>
Instrument	<p>Single cells were analyzed by FACS-Aria III (BD) with a 100 µm nozzle.</p>
Software	<p>Data were analyzed with the FACS DIVA software v6.1.3.</p>
Cell population abundance	<p>Abundance of intestinal cell populations (from live cells = 40-60%) are reported in this manuscript and source data (Fig. 4g, F, Extended Data Fig. 9a). When possible purity of post-sort fractions were checked by briefly re-running a small amount of sample. Purity was usually 90-95%.</p>
Gating strategy	<p>Single cells were gated according to their FSC-A (front scatter area) and SSC-A (side scatter area). Singlets were gated dependent on the FSC-W (front scatter width) and FSC-H (front scatter height) and SSC-W and SSC-H and dead cells were excluded using the marker7AAD (eBioscience). To obtain FVF-enriched small intestinal crypt cell samples for single-cell RNA sequencing, 30,000 FVF + (FVF<sub>low</sub> and FVF<sub>hi</sub>) cells were sorted followed by sorting 30,000 live crypt cells per sample.</p>

☒ Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.